<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Nat Med</journal-id>
        <journal-id journal-id-type="iso-abbrev">Nat. Med</journal-id>
        <journal-id journal-id-type="pmc-domain-id">981</journal-id>
        <journal-id journal-id-type="pmc-domain">npgopen</journal-id>
        <journal-title-group>
          <journal-title>Nature Medicine</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1078-8956</issn>
        <issn pub-type="epub">1546-170X</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>Nature Portfolio</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC6898788</article-id>
        <article-id pub-id-type="pmcid-ver">PMC6898788.2</article-id>
        <article-id pub-id-type="pmcaid">6898788</article-id>
        <article-id pub-id-type="pmcaiid">6900205</article-id>
        <article-id pub-id-type="pmid">31792460</article-id>
        <article-id pub-id-type="doi">10.1038/s41591-019-0654-5</article-id>
        <article-id pub-id-type="publisher-id">654</article-id>
        <article-version article-version-type="pmc-version">2</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author" equal-contrib="yes">
            <name name-style="western">
              <surname>Liu</surname>
              <given-names initials="D">David</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author" equal-contrib="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8859-4103</contrib-id>
            <name name-style="western">
              <surname>Schilling</surname>
              <given-names initials="B">Bastian</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
            <xref ref-type="aff" rid="Aff4">4</xref>
            <xref ref-type="aff" rid="Aff5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Liu</surname>
              <given-names initials="D">Derek</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sucker</surname>
              <given-names initials="A">Antje</given-names>
            </name>
            <xref ref-type="aff" rid="Aff4">4</xref>
            <xref ref-type="aff" rid="Aff5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Livingstone</surname>
              <given-names initials="E">Elisabeth</given-names>
            </name>
            <xref ref-type="aff" rid="Aff4">4</xref>
            <xref ref-type="aff" rid="Aff5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jerby-Arnon</surname>
              <given-names initials="L">Livnat</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zimmer</surname>
              <given-names initials="L">Lisa</given-names>
            </name>
            <xref ref-type="aff" rid="Aff4">4</xref>
            <xref ref-type="aff" rid="Aff5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Gutzmer</surname>
              <given-names initials="R">Ralf</given-names>
            </name>
            <xref ref-type="aff" rid="Aff7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Satzger</surname>
              <given-names initials="I">Imke</given-names>
            </name>
            <xref ref-type="aff" rid="Aff7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Loquai</surname>
              <given-names initials="C">Carmen</given-names>
            </name>
            <xref ref-type="aff" rid="Aff8">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Grabbe</surname>
              <given-names initials="S">Stephan</given-names>
            </name>
            <xref ref-type="aff" rid="Aff8">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Vokes</surname>
              <given-names initials="N">Natalie</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Margolis</surname>
              <given-names initials="CA">Claire A.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Conway</surname>
              <given-names initials="J">Jake</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>He</surname>
              <given-names initials="MX">Meng Xiao</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
            <xref ref-type="aff" rid="Aff9">9</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Elmarakeby</surname>
              <given-names initials="H">Haitham</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Dietlein</surname>
              <given-names initials="F">Felix</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1754-2319</contrib-id>
            <name name-style="western">
              <surname>Miao</surname>
              <given-names initials="D">Diana</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Tracy</surname>
              <given-names initials="A">Adam</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Gogas</surname>
              <given-names initials="H">Helen</given-names>
            </name>
            <xref ref-type="aff" rid="Aff10">10</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Goldinger</surname>
              <given-names initials="SM">Simone M.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff11">11</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5316-0241</contrib-id>
            <name name-style="western">
              <surname>Utikal</surname>
              <given-names initials="J">Jochen</given-names>
            </name>
            <xref ref-type="aff" rid="Aff12">12</xref>
            <xref ref-type="aff" rid="Aff13">13</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7945-5846</contrib-id>
            <name name-style="western">
              <surname>Blank</surname>
              <given-names initials="CU">Christian U.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff14">14</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Rauschenberg</surname>
              <given-names initials="R">Ricarda</given-names>
            </name>
            <xref ref-type="aff" rid="Aff15">15</xref>
            <xref ref-type="aff" rid="Aff16">16</xref>
            <xref ref-type="aff" rid="Aff17">17</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>von Bubnoff</surname>
              <given-names initials="D">Dagmar</given-names>
            </name>
            <xref ref-type="aff" rid="Aff18">18</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Krackhardt</surname>
              <given-names initials="A">Angela</given-names>
            </name>
            <xref ref-type="aff" rid="Aff5">5</xref>
            <xref ref-type="aff" rid="Aff19">19</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Weide</surname>
              <given-names initials="B">Benjamin</given-names>
            </name>
            <xref ref-type="aff" rid="Aff20">20</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Haferkamp</surname>
              <given-names initials="S">Sebastian</given-names>
            </name>
            <xref ref-type="aff" rid="Aff21">21</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kiecker</surname>
              <given-names initials="F">Felix</given-names>
            </name>
            <xref ref-type="aff" rid="Aff22">22</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Izar</surname>
              <given-names initials="B">Ben</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Garraway</surname>
              <given-names initials="L">Levi</given-names>
            </name>
            <xref ref-type="aff" rid="Aff23">23</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3293-3158</contrib-id>
            <name name-style="western">
              <surname>Regev</surname>
              <given-names initials="A">Aviv</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3402-0478</contrib-id>
            <name name-style="western">
              <surname>Flaherty</surname>
              <given-names initials="K">Keith</given-names>
            </name>
            <xref ref-type="aff" rid="Aff24">24</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Paschen</surname>
              <given-names initials="A">Annette</given-names>
            </name>
            <xref ref-type="aff" rid="Aff4">4</xref>
            <xref ref-type="aff" rid="Aff5">5</xref>
          </contrib>
          <contrib contrib-type="author" corresp="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0201-4444</contrib-id>
            <name name-style="western">
              <surname>Van Allen</surname>
              <given-names initials="EM">Eliezer M.</given-names>
            </name>
            <address>
              <email>eliezerm_vanallen@dfci.harvard.edu</email>
            </address>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author" corresp="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3524-7858</contrib-id>
            <name name-style="western">
              <surname>Schadendorf</surname>
              <given-names initials="D">Dirk</given-names>
            </name>
            <address>
              <email>dirk.schadendorf@uk-essen.de</email>
            </address>
            <xref ref-type="aff" rid="Aff4">4</xref>
            <xref ref-type="aff" rid="Aff5">5</xref>
          </contrib>
          <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2106 9910</institution-id><institution-id institution-id-type="GRID">grid.65499.37</institution-id><institution>Dana-Farber Cancer Institute, </institution></institution-wrap>Boston, MA USA </aff>
          <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.66859.34</institution-id><institution>Broad Institute of Harvard and MIT, </institution></institution-wrap>Cambridge, MA USA </aff>
          <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1378 7891</institution-id><institution-id institution-id-type="GRID">grid.411760.5</institution-id><institution>Department of Dermatology, </institution><institution>University Hospital Würzburg, </institution></institution-wrap>Würzburg, Germany </aff>
          <aff id="Aff4"><label>4</label>Department of Dermatology, University Hospital, Essen, Germany </aff>
          <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0492 0584</institution-id><institution-id institution-id-type="GRID">grid.7497.d</institution-id><institution>German Cancer Consortium of Translational Cancer Research, </institution><institution>German Cancer Research Center, </institution></institution-wrap>Heidelberg, Germany </aff>
          <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution>Harvard Medical School, </institution></institution-wrap>Boston, MA USA </aff>
          <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9529 9877</institution-id><institution-id institution-id-type="GRID">grid.10423.34</institution-id><institution>Skin Cancer Center Hannover, Department of Dermatology and Allergy, </institution><institution>Hannover Medical School, </institution></institution-wrap>Hannover, Germany </aff>
          <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.410607.4</institution-id><institution>Department of Dermatology, </institution><institution>University Medical Center, </institution></institution-wrap>Mainz, Germany </aff>
          <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution>Biophysics Program, </institution><institution>Harvard University, </institution></institution-wrap>Cambridge, MA USA </aff>
          <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2155 0800</institution-id><institution-id institution-id-type="GRID">grid.5216.0</institution-id><institution>First Department of Medicine, </institution><institution>National and Kapodistrian University of Athens, </institution></institution-wrap>Athens, Greece </aff>
          <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0478 9977</institution-id><institution-id institution-id-type="GRID">grid.412004.3</institution-id><institution>Department of Dermatology, </institution><institution>University Hospital Zürich, </institution></institution-wrap>Zürich, Switzerland </aff>
          <aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2162 1728</institution-id><institution-id institution-id-type="GRID">grid.411778.c</institution-id><institution>Department of Dermatology, </institution><institution>University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, </institution></institution-wrap>Mannheim, Germany </aff>
          <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0492 0584</institution-id><institution-id institution-id-type="GRID">grid.7497.d</institution-id><institution>Skin Cancer Unit, </institution><institution>German Cancer Research Center, </institution></institution-wrap>Heidelberg, Germany </aff>
          <aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.430814.a</institution-id><institution>Department of Medical Oncology, </institution><institution>The Netherlands Cancer Institute, </institution></institution-wrap>Amsterdam, the Netherlands </aff>
          <aff id="Aff15"><label>15</label>Skin Cancer Center at the University Cancer Centre, Department of Dermatology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany </aff>
          <aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0328 4908</institution-id><institution-id institution-id-type="GRID">grid.5253.1</institution-id><institution>National Center for Tumor Diseases, </institution></institution-wrap>Dresden, Germany </aff>
          <aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0492 0584</institution-id><institution-id institution-id-type="GRID">grid.7497.d</institution-id><institution>German Cancer Research Centre, </institution></institution-wrap>Heidelberg, Germany </aff>
          <aff id="Aff18"><label>18</label>Department of Dermatology, Medical Center- University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany </aff>
          <aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ISNI">0000000123222966</institution-id><institution-id institution-id-type="GRID">grid.6936.a</institution-id><institution>Medizinische Klinik III, Klinikum Rechts der Isar, </institution><institution>Technische Universität München, </institution></institution-wrap>Munich, Germany </aff>
          <aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0196 8249</institution-id><institution-id institution-id-type="GRID">grid.411544.1</institution-id><institution>Department of Dermatology, </institution><institution>University Medical Center Tübingen, </institution></institution-wrap>Tübingen, Germany </aff>
          <aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9194 7179</institution-id><institution-id institution-id-type="GRID">grid.411941.8</institution-id><institution>Department of Dermatology, </institution><institution>University Hospital Regensburg, </institution></institution-wrap>Regensburg, Germany </aff>
          <aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2218 4662</institution-id><institution-id institution-id-type="GRID">grid.6363.0</institution-id><institution>Department of Dermatology, </institution><institution>University Hospital Berlin, </institution></institution-wrap>Berlin, Germany </aff>
          <aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 2220 2544</institution-id><institution-id institution-id-type="GRID">grid.417540.3</institution-id><institution>Eli Lilly and Co., </institution></institution-wrap>Indianapolis, IN USA </aff>
          <aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0386 9924</institution-id><institution-id institution-id-type="GRID">grid.32224.35</institution-id><institution>Massachusetts General Hospital, </institution></institution-wrap>Boston, MA USA </aff>
        </contrib-group>
        <pub-date pub-type="epub">
          <day>2</day>
          <month>12</month>
          <year>2019</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <year>2019</year>
        </pub-date>
        <volume>25</volume>
        <issue>12</issue>
        <issue-id pub-id-type="pmc-issue-id">347318</issue-id>
        <fpage>1916</fpage>
        <lpage>1927</lpage>
        <history>
          <date date-type="received">
            <day>25</day>
            <month>3</month>
            <year>2019</year>
          </date>
          <date date-type="accepted">
            <day>17</day>
            <month>10</month>
            <year>2019</year>
          </date>
        </history>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>02</day>
              <month>12</month>
              <year>2019</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>10</day>
              <month>12</month>
              <year>2019</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-04-02 10:25:14.617">
              <day>02</day>
              <month>04</month>
              <year>2024</year>
            </date>
          </event>
          <event event-type="pmc-version" specific-use="live">
            <article-id pub-id-type="pmcaiid">6898788</article-id>
            <article-id pub-id-type="doi">10.1038/s41591-019-0654-5</article-id>
            <article-id pub-id-type="manuscript-id">NIHMS1541324</article-id>
            <article-version>1</article-version>
            <pub-date>
              <day>02</day>
              <month>12</month>
              <year>2019</year>
            </pub-date>
          </event>
          <event event-type="pmc-version" specific-use="live">
            <article-id pub-id-type="pmcaiid">6900205</article-id>
            <article-id pub-id-type="doi">10.1038/s41591-019-0654-5</article-id>
            <article-version>2</article-version>
            <pub-date>
              <day>02</day>
              <month>12</month>
              <year>2019</year>
            </pub-date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>© The Author(s) 2019</copyright-statement>
          <license license-type="OpenAccess">
            <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41591_2019_Article_654.pdf"/>
        <related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="correction-forward" xml:lang="en" xlink:title="correction" journal-id="Nat Med" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC7358200">
          <article-title>Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma</article-title>
          <volume>26</volume>
          <issue>7</issue>
          <date>
            <day>19</day>
            <month>6</month>
            <year>2020</year>
          </date>
          <fpage>1147</fpage>
          <lpage>1147</lpage>
          <source>Nature Medicine</source>
          <pub-id pub-id-type="doi">10.1038/s41591-020-0975-4</pub-id>
          <pub-id pub-id-type="pmcid">PMC7358200</pub-id>
          <pub-id pub-id-type="pmid">32561875</pub-id>
        </related-article>
        <abstract id="Abs1">
          <p id="Par1">Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study, we analyzed a clinically annotated cohort of patients with melanoma (<italic toggle="yes">n</italic> = 144) treated with anti-PD1 ICB, with whole-exome and whole-transcriptome sequencing of pre-treatment tumors. We found that tumor mutational burden as a predictor of response was confounded by melanoma subtype, whereas multiple novel genomic and transcriptomic features predicted selective response, including features associated with MHC-I and MHC-II antigen presentation. Furthermore, previous anti-CTLA4 ICB exposure was associated with different predictors of response compared to tumors that were naive to ICB, suggesting selective immune effects of previous exposure to anti-CTLA4 ICB. Finally, we developed parsimonious models integrating clinical, genomic and transcriptomic features to predict intrinsic resistance to anti-PD1 ICB in individual tumors, with validation in smaller independent cohorts limited by the availability of comprehensive data. Broadly, we present a framework to discover predictive features and build models of ICB therapeutic response.</p>
        </abstract>
        <abstract id="Abs2" abstract-type="web-summary">
          <p id="Par2">Analysis of fully clinically annotated and sequenced melanoma tumor samples collected before anti-PD1 treatment suggests that determinants of response differ on the basis of previous anti-CTLA4 therapy, and that tumor mutational burden may not be a strong predictor of response across melanoma subtypes.</p>
        </abstract>
        <kwd-group kwd-group-type="npg-subject">
          <title>Subject terms</title>
          <kwd>Cancer genomics</kwd>
          <kwd>Melanoma</kwd>
          <kwd>Computational biology and bioinformatics</kwd>
        </kwd-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001659</institution-id>
                <institution>Deutsche Forschungsgemeinschaft (German Research Foundation)</institution>
              </institution-wrap>
            </funding-source>
            <award-id>SCHA 422/17-1; PA 2376/1-1; HO 6389/2-1 (KFO 337)</award-id>
            <principal-award-recipient>
              <name name-style="western">
                <surname>Schadendorf</surname>
                <given-names>Dirk</given-names>
              </name>
            </principal-award-recipient>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000982</institution-id>
                <institution>name&gt;Conquer Cancer Foundation (Conquer Cancer Foundation of the American Society of Clinical Oncology)</institution>
              </institution-wrap>
            </funding-source>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100011619</institution-id>
                <institution>Society for Immunotherapy of Cancer (SITC)</institution>
              </institution-wrap>
            </funding-source>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100001021</institution-id>
                <institution>Damon Runyon Cancer Research Foundation (Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation)</institution>
              </institution-wrap>
            </funding-source>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000057</institution-id>
                <institution>U.S. Department of Health &amp; Human Services | NIH | National Institute of General Medical Sciences (NIGMS)</institution>
              </institution-wrap>
            </funding-source>
            <award-id>T32 GM008313</award-id>
            <principal-award-recipient>
              <name name-style="western">
                <surname>He</surname>
                <given-names>Meng Xiao</given-names>
              </name>
            </principal-award-recipient>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution>NIH (funding source); R01 CA227388, U01 CA233100 (grant ID #s) BroadNext10 (funding source, no ID)</institution>
            </funding-source>
          </award-group>
        </funding-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>issue-copyright-statement</meta-name>
            <meta-value>© The Author(s), under exclusive licence to Springer Nature Limited 2019</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec id="Sec1">
        <title>Main</title>
        <p id="Par3">While ICB has resulted in durable clinical response in multiple tumor types<sup><xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR7">7</xref></sup>, only a subset of patients respond, and predictors of response are not fully characterized. Both tumor-intrinsic and tumor-extrinsic biomarkers of response and resistance to ICB in melanoma have been proposed, including tumor mutational burden (TMB) and neoantigen load<sup><xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR11">11</xref></sup>, immunohistological detection of PD-L1 and CD8<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> and genetic alterations affecting antigen presentation<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup>, interferon (IFN)-γ signaling pathways<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, alternative survival and proliferation pathways<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup> and aneuploidy<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. Gene expression signatures expressed in tumors<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> and the tumor immune microenvironment<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> have also been implicated. However, these observations have often been made in preclinical models or in small clinical cohorts without validation in larger, independent cohorts of patients with melanoma. Furthermore, whether these observations are exclusive to a specific ICB regimen (that is, anti-PD1, anti-CTLA4 or a combination of these) is incompletely characterized. Broadly, the expanding suite of pathways that has been invoked to mediate selective ICB response in melanoma indicates that integrated systems biology models to predict response and survival are necessary, but these have yet to be well developed.</p>
        <p id="Par4">Clinically, the optimal role of anti-CTLA4 in conjunction<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> or sequentially<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> with anti-PD1 ICB is unclear. Understanding the differential biology underlying the response to anti-PD1 ICB in tumors with and without previous anti-CTLA4 therapy may inform the rational design of combination therapies and optimize therapy selection for individual patients.</p>
        <p id="Par5">Thus, we performed an integrative study employing genomic, transcriptomic and clinical data from a comprehensively clinically annotated and sequenced cohort of 144 patients with advanced melanoma undergoing anti-PD1 ICB with and without previous anti-CTLA4 ICB to discover biomarkers of response and resistance, and develop clinically applicable parsimonious predictive models.</p>
      </sec>
      <sec id="Sec2" sec-type="results">
        <title>Results</title>
        <sec id="Sec3">
          <title>Genomic and clinical cohort characteristics and melanoma subtypes</title>
          <p id="Par6">We identified 206 patients diagnosed with advanced melanoma and treated with anti-PD1 ICB, and performed whole-exome sequencing (WES) on matched pretreatment tumor samples and normal tissue<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>, and whole-transcriptome sequencing (RNA-seq) on available pretreatment tumor tissue. After quality control (<xref rid="Sec9" ref-type="sec">Methods</xref>), WES data from 144 patients and RNA-seq data from 121 patients were available for final evaluation (Extended Data Fig. <xref rid="Fig6" ref-type="fig">1</xref>). Best objective response (BOR) to anti-PD1 ICB using RECIST (v.1.1) criteria (<xref rid="Sec9" ref-type="sec">Methods</xref>) included 45% with progressive disease (PD), 14% with stable disease (SD), 3% with mixed response (MR), 26% with partial response (PR) and 12% with complete response (CR; Fig. <xref rid="Fig1" ref-type="fig">1a</xref>), for an overall response rate of 38%. Overall, 73% were cutaneous melanomas, 13% were of occult origin, 7% were mucosal and 7% were acral in origin. A total of 44% (<italic toggle="yes">n</italic> = 64) of patients had previous treatment with ipilimumab, whereas 56% (<italic toggle="yes">n</italic> = 80) were naive to ipilimumab. The median follow-up for survival was 29.9 months. Other clinical characteristics are detailed in Table <xref rid="Tab1" ref-type="table">1</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Cohort genomic and clinical characteristics and association of TMB with response.</title><p><bold>a</bold>, CoMut plot showing association between clinical and genomic characteristics. Each column represents a tumor. Tumors are ordered by best RECIST criteria response (CR, PR, PD, SD or MR), and within each response subgroup by decreasing nonsynonymous (Nonsyn) mutational load (top row). Nonsynonymous mutational burden is further subdivided into clonal (purple) and subclonal (light purple) mutational load. Mutational signatures (sig) refer to the inferred relative contribution of UV-induced mutations, alkylating DNA damage process and other mutational signatures (aging+). The primary type of melanoma (skin, occult, acral or mucosal) is indicated. Tumor purity is the inferred proportion of the tumor sample that is from cancer cells compared to other cell types (<xref rid="Sec9" ref-type="sec">Methods</xref>). The dominant mutational signature (that is, the mutational signature associated with the highest proportion of mutations) is indicated. Mutations in <italic toggle="yes">BRAF</italic>, <italic toggle="yes">NRAS</italic> and <italic toggle="yes">NF1</italic> are shown for each tumor. <bold>b</bold>, Mutational load (mut load) in progressors (<italic toggle="yes">n</italic> = 65 patients), responders (<italic toggle="yes">n</italic> = 55 patients) and patients with SD and MR (<italic toggle="yes">n</italic> = 24 patients). Nonsynonymous mutational load is higher in responders (CR and PR) than in progressors (two-sided MWW, <italic toggle="yes">P</italic> = 0.026), but is not significantly different between responders and patients having SD or MR as the best RECIST response (two-sided MWW, <italic toggle="yes">P</italic> = 0.14). <bold>c</bold>, Mutational load by melanoma type. Different melanoma types have different mutational loads (Kruskal–Wallis, <italic toggle="yes">P</italic> = 2.4 × 10<sup>−</sup><sup>5</sup>): mutational load is higher in cutaneous and occult melanomas (<italic toggle="yes">n</italic> = 124 patients) than in acral and mucosal melanomas (<italic toggle="yes">n</italic> = 20 patients; median 297.5 versus 58; two-sided MWW, <italic toggle="yes">P</italic> = 1.1 × 10<sup>−6</sup>). <bold>d</bold>, Response to anti-PD1 ICB by melanoma type. Cutaneous and occult melanomas (<italic toggle="yes">n</italic> = 124 patients) have higher response rates (~40% CR and PR) versus acral and mucosal melanomas (<italic toggle="yes">n</italic> = 20 patients, 20%; two-sided Fisher’s exact test, <italic toggle="yes">P</italic> = 0.06). <bold>e</bold>, Mutational load in responders versus progressors stratified by melanoma type. There was no significant difference between responder and progressor mutational loads when melanomas were stratified by type (two-sided MWW; progressors versus responders (PD/R): skin (<italic toggle="yes">n</italic> = 42/43), <italic toggle="yes">P</italic> = 0.27; occult (<italic toggle="yes">n</italic> = 10/8), <italic toggle="yes">P</italic> = 0.35; acral (<italic toggle="yes">n</italic> = 7/2), <italic toggle="yes">P</italic> = 0.19; mucosal (<italic toggle="yes">n</italic> = 6/2), <italic toggle="yes">P</italic> = 0.40). Mutational load was also not a significant predictor of response in combined logistic regression after adjusting for melanoma type (<italic toggle="yes">P</italic> = 0.24). <bold>f</bold>, TMB in responders versus nonresponders, stratified by skin or occult melanomas versus mucosal or acral melanomas. Within each subgroup, responders trended toward having higher TMB than nonresponders (cutaneous/occult (<italic toggle="yes">n</italic> = 52 progressors and 51 responders): MWW, <italic toggle="yes">P</italic> = 0.14; mucosal/acral (<italic toggle="yes">n</italic> = 13 progressors and 4 responders): MWW, <italic toggle="yes">P</italic> = 0.08). Notably, responders with mucosal or acral melanoma (<italic toggle="yes">n</italic> = 4) had a lower mutational load than progressors with cutaneous or occult melanoma (<italic toggle="yes">n</italic> = 52; MWW, <italic toggle="yes">P</italic> = 0.03). Boxplots: box limits indicate the IQR (25th to 75th percentiles), with a center line indicating the median. Whiskers show the value ranges up to 1.5 × IQR above the 75th or below the 25th percentiles, with outliers beyond those ranges shown as individual points. *<italic toggle="yes">P</italic> &lt; 0.05, **<italic toggle="yes">P</italic> &lt; 0.01, ***<italic toggle="yes">P</italic> &lt; 0.001. NS, not significant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d30e1046" position="float" orientation="portrait" xlink:href="41591_2019_654_Fig1_HTML.jpg"/></fig><table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Cohort clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"><italic toggle="yes">n</italic> (%)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Total cohort</td><td colspan="1" rowspan="1">144 (100)</td></tr><tr><td colspan="2" rowspan="1">Drug received</td></tr><tr><td colspan="1" rowspan="1"> Nivolumab</td><td colspan="1" rowspan="1">59 (41.0)</td></tr><tr><td colspan="1" rowspan="1"> Pembrolizumab</td><td colspan="1" rowspan="1">85 (59.0)</td></tr><tr><td colspan="2" rowspan="1">Sex</td></tr><tr><td colspan="1" rowspan="1"> Female</td><td colspan="1" rowspan="1">60 (41.7)</td></tr><tr><td colspan="1" rowspan="1"> Male</td><td colspan="1" rowspan="1">84 (58.3)</td></tr><tr><td colspan="2" rowspan="1">Stage</td></tr><tr><td colspan="1" rowspan="1"> Unresectable stage III</td><td colspan="1" rowspan="1">10 (6.9)</td></tr><tr><td colspan="1" rowspan="1"> M1a</td><td colspan="1" rowspan="1">8 (5.6)</td></tr><tr><td colspan="1" rowspan="1"> M1b</td><td colspan="1" rowspan="1">18 (12.5)</td></tr><tr><td colspan="1" rowspan="1"> M1c</td><td colspan="1" rowspan="1">108 (75.0)</td></tr><tr><td colspan="2" rowspan="1">Active brain metastases</td></tr><tr><td colspan="1" rowspan="1"> Yes</td><td colspan="1" rowspan="1">16 (11.1)</td></tr><tr><td colspan="1" rowspan="1"> No</td><td colspan="1" rowspan="1">128 (88.9)</td></tr><tr><td colspan="2" rowspan="1">Elevated LDH</td></tr><tr><td colspan="1" rowspan="1"> Yes</td><td colspan="1" rowspan="1">71 (49.3)</td></tr><tr><td colspan="1" rowspan="1"> No</td><td colspan="1" rowspan="1">70 (48.6)</td></tr><tr><td colspan="1" rowspan="1"> Unknown</td><td colspan="1" rowspan="1">3 (2.1)</td></tr><tr><td colspan="2" rowspan="1">ECOG performance status</td></tr><tr><td colspan="1" rowspan="1"> 0</td><td colspan="1" rowspan="1">99 (68.8)</td></tr><tr><td colspan="1" rowspan="1"> 1</td><td colspan="1" rowspan="1">37 (25.7)</td></tr><tr><td colspan="1" rowspan="1"> 2</td><td colspan="1" rowspan="1">2 (1.4)</td></tr><tr><td colspan="1" rowspan="1"> 3</td><td colspan="1" rowspan="1">1 (0.7)</td></tr><tr><td colspan="1" rowspan="1"> Unknown</td><td colspan="1" rowspan="1">5 (3.5)</td></tr><tr><td colspan="2" rowspan="1">Primary melanoma</td></tr><tr><td colspan="1" rowspan="1"> Cutaneous</td><td colspan="1" rowspan="1">105 (72.9)</td></tr><tr><td colspan="1" rowspan="1"> Occult</td><td colspan="1" rowspan="1">19 (13.2)</td></tr><tr><td colspan="1" rowspan="1"> Acral</td><td colspan="1" rowspan="1">10 (6.9)</td></tr><tr><td colspan="1" rowspan="1"> Mucosal</td><td colspan="1" rowspan="1">10 (6.9)</td></tr><tr><td colspan="2" rowspan="1">Received anti-PD1 ICB</td></tr><tr><td colspan="1" rowspan="1"> First line</td><td colspan="1" rowspan="1">71 (49.3)</td></tr><tr><td colspan="1" rowspan="1"> Second line or later</td><td colspan="1" rowspan="1">73 (50.7)</td></tr><tr><td colspan="2" rowspan="1">Previous ipilimumab</td></tr><tr><td colspan="1" rowspan="1"> Yes</td><td colspan="1" rowspan="1">60 (41.7)</td></tr><tr><td colspan="1" rowspan="1"> No</td><td colspan="1" rowspan="1">84 (58.3)</td></tr></tbody></table><table-wrap-foot><p>The number of patients with the given characteristic is shown, with the number in parentheses indicating the percentage of patients represented. ECOG, Eastern Cooperative Oncology Group.</p></table-wrap-foot></table-wrap></p>
          <p id="Par7">Overall the median nonsynonymous TMB was 6.5 mutations per Mb (250.5 mutations per exome), with an interquartile range (IQR) of 2.0–14.4 mutations per Mb (77.75–578.5 mutations per exome). Overall, 39% of tumors had <italic toggle="yes">BRAF</italic> mutations, 30% had <italic toggle="yes">NRAS</italic> mutations and 17% had <italic toggle="yes">NF1</italic> mutations (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). The median tumor purity (the proportion of sample DNA from tumor cells) was 0.67 (IQR 0.46–0.83) and the median tumor heterogeneity (the proportion of subclonal mutations) was 0.17 (IQR 0.12–0.25). The median purity-corrected tumor ploidy (<xref rid="Sec9" ref-type="sec">Methods</xref>) was 2.15 (IQR 2.01–3.12), with 38% of tumors inferred to have genome doubling, consistent with previous reports<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. The predominant mutational signature in most tumors was related to ultraviolet (UV) exposure<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> (69% related to UV, 3% related to alkylating chemotherapy<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> and 28% related to another predominant mutational signature, mostly associated with aging<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>; Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). Individual tumor characteristics are detailed in Supplementary Table <xref rid="MOESM4" ref-type="media">1</xref>.</p>
          <p id="Par8">To discover differential features associated with response, we compared clinical responders (<italic toggle="yes">n</italic> = 55) to progressors (<italic toggle="yes">n</italic> = 65), excluding patients with SD (<italic toggle="yes">n</italic> = 20) and MR (<italic toggle="yes">n</italic> = 4) as the BOR. Overall survival (OS) and progression-free survival (PFS) were significantly different between these groups (log-rank <italic toggle="yes">P</italic> &lt; 0.00001 for both comparisons; Extended Data Fig. <xref rid="Fig7" ref-type="fig">2a,b</xref>).</p>
          <p id="Par9">TMB was higher in responders than in progressors (Mann–Whitney–Wilcoxon (MWW), <italic toggle="yes">P</italic> = 0.026; Fig. <xref rid="Fig1" ref-type="fig">1b</xref>), but there was substantial overlap between responders and progressors. We hypothesized that the relationship between response and TMB might further be confounded by melanoma subtype. TMB was significantly different between different melanoma subtypes (Kruskal–Wallis, <italic toggle="yes">P</italic> = 2.4 × 10<sup>−5</sup>; Fig. <xref rid="Fig1" ref-type="fig">1c</xref>), with cutaneous and occult melanomas having similar and higher TMB than acral and mucosal melanomas<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> (median of 297.5 versus 58, nonsynonymous mutations; MWW, <italic toggle="yes">P</italic> = 1.1 × 10<sup>−6</sup>), with a higher response rate (~40% versus ~20%; Fisher’s exact test, <italic toggle="yes">P</italic> = 0.06; Fig. <xref rid="Fig1" ref-type="fig">1d</xref>). When stratified by melanoma subtype, responders did not have significantly higher TMB than nonresponders (Fig. <xref rid="Fig1" ref-type="fig">1e</xref>), and, in multivariate logistic regression adjusting for melanoma subtype, TMB was not a significant predictor (<italic toggle="yes">P</italic> = 0.24). Strikingly, responders with mucosal or acral melanoma had a lower TMB than progressors with cutaneous or occult melanoma (MWW, <italic toggle="yes">P</italic> = 0.03; Fig. <xref rid="Fig1" ref-type="fig">1f</xref>), suggesting that disease subtype confounds the association between TMB and response to anti-PD1 therapy.</p>
        </sec>
        <sec id="Sec4">
          <title>Genomic and transcriptomic features associated with response</title>
          <p id="Par10">Higher tumor purity and heterogeneity were associated with progression (MWW, <italic toggle="yes">P</italic> = 0.04 and <italic toggle="yes">P</italic> = 0.02, respectively; Fig. <xref rid="Fig2" ref-type="fig">2a,c</xref>), whereas ploidy was lower in progressors (MWW, <italic toggle="yes">P</italic> = 0.04; Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). The proportion of the tumor genome with copy number alterations (CNAs) trended toward being higher in patients with PD (MWW, <italic toggle="yes">P</italic> = 0.09; Extended Data Fig. <xref rid="Fig7" ref-type="fig">2c</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Genomic and transcriptomic features associated with response.</title><p>All <italic toggle="yes">P</italic> values are unadjusted, unless otherwise indicated. <bold>a</bold>, Tumor heterogeneity, defined as the proportion of subclonal mutations in each tumor (<xref rid="Sec9" ref-type="sec">Methods</xref>), in responders (CR or PR) versus progressors (PD). Progressors (<italic toggle="yes">n</italic> = 65 patients) had greater heterogeneity than responders (<italic toggle="yes">n</italic> = 55 patients; two-sided MWW, <italic toggle="yes">P</italic> = 0.02). <bold>b</bold>, Tumor ploidy, defined as the overall genomic copy number (a normal diploid cell has a copy number of 2; <xref rid="Sec9" ref-type="sec">Methods</xref>), in responders versus progressors. Responders (<italic toggle="yes">n</italic> = 55 patients) had higher tumor ploidy than progressors (<italic toggle="yes">n</italic> = 65 patients; two-sided MWW, <italic toggle="yes">P</italic> = 0.04). <bold>c</bold>, Tumor purity, defined as the proportion of DNA from tumor versus other cells in the sample (<xref rid="Sec9" ref-type="sec">Methods</xref>), in responders versus progressors. Progressors (<italic toggle="yes">n</italic> = 65 patients) had higher tumor purity than responders (<italic toggle="yes">n</italic> = 55 patients; two-sided MWW, <italic toggle="yes">P</italic> = 0.04). <bold>d</bold>, Response versus progression in <italic toggle="yes">TAP2-</italic>amplified tumors versus other tumors. <italic toggle="yes">TAP2</italic> amplification (<italic toggle="yes">n</italic> = 6 patients) was associated with response (two-sided Fisher’s exact test, <italic toggle="yes">P</italic> = 0.008). <bold>e</bold>, Response versus progression in tumors with amplified MHC-I HLA genes (<italic toggle="yes">HLA-A</italic>, <italic toggle="yes">HLA-B</italic> or <italic toggle="yes">HLA-C</italic>) versus other tumors. MHC-I HLA amplification (<italic toggle="yes">n</italic> = 6 patients) was associated with response (two-sided Fisher’s exact test, <italic toggle="yes">P</italic> = 0.008). <bold>f</bold>, Venn diagram showing the overlap of <italic toggle="yes">TAP2</italic>-amplified tumors and tumors with amplification of MHC-I HLA genes. Four tumors had amplifications on chromosome 6, including the MHC-I genes <italic toggle="yes">HLA-A</italic>, <italic toggle="yes">HLA-B</italic>, <italic toggle="yes">HLA-C</italic> and <italic toggle="yes">TAP2</italic> and two tumors each had amplifications in one but not the other region, for a total of eight tumors with amplifications in either. <bold>g</bold>, Difference in the median expression and two-sided MWW <italic toggle="yes">P</italic> value of association between 938 immune-related genes<sup><xref ref-type="bibr" rid="CR56">56</xref></sup> and features in responders versus progressors. Expression levels of MHC-II HLA genes (red), MHC-I HLA genes and antigen-presentation machinery (APM)-related genes (orange) are shown. <bold>h</bold>, Hierarchical clustering of the correlation matrix between genomic, clinical and transcriptomic features associated with response. Color indicates the Pearson correlation between features, from perfect negative correlation (Pearson, <italic toggle="yes">r</italic> = −1, blue) to perfect positive correlation (Pearson, <italic toggle="yes">r</italic> = 1, red). An immune-related cluster of MHC-I- and MHC-II-related gene expression is observed, with subclusters of MHC-I and MHC-II genes. Mutational and neoantigen load are highly correlated and form a cluster independently from the immune cluster (for example, Pearson correlation, <italic toggle="yes">r</italic> = 0.15, <italic toggle="yes">P</italic> = 0.11 between ssGSEA of MHC-II HLA genes and nonsynonymous mutational load). Purity is negatively correlated with the immune cluster and is independent of ploidy and heterogeneity. The sample size for each correlation depended on the number of available data points: correlations involving exclusively genomic or clinical data had <italic toggle="yes">n</italic> = 144 tumor samples, whereas correlations involving transcriptomic features had <italic toggle="yes">n</italic> = 121 tumor samples with data available. Tx, treatment. Boxplots: box limits indicate the IQR (25th to 75th percentile), with a center line indicating the median. Whiskers show the value ranges up to 1.5 × IQR above the 75th or below the 25th percentile, with outliers beyond those ranges shown as individual points. *<italic toggle="yes">P</italic> &lt; 0.05, **<italic toggle="yes">P</italic> &lt; 0.01, ***<italic toggle="yes">P</italic> &lt; 0.001; NS, not significant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d30e1588" position="float" orientation="portrait" xlink:href="41591_2019_654_Fig2_HTML.jpg"/></fig></p>
          <p id="Par11">Given these observations, we performed an unbiased analysis for single-gene predictors of response to anti-PD1 ICB across all mutated genes detected in this cohort. After multiple-hypothesis test correction, no genes were significantly associated with response or resistance to therapy (Extended Data Fig. <xref rid="Fig8" ref-type="fig">3a</xref> and Supplementary Table <xref rid="MOESM4" ref-type="media">2</xref>), highlighting the large sample sizes needed for adequate power to detect these associations<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. We observed only rare mutations in major histocompatibility complex class I (MHC-I) antigen-presentation genes (<italic toggle="yes">TAP1</italic>, <italic toggle="yes">TAP2</italic>, <italic toggle="yes">B2M</italic>, <italic toggle="yes">HLA-A</italic>, <italic toggle="yes">HLA-B</italic> and <italic toggle="yes">HLA-C</italic>)<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>. Mutations in <italic toggle="yes">SERPINB3</italic> or <italic toggle="yes">SERPINB4</italic><sup><xref ref-type="bibr" rid="CR29">29</xref></sup> were not associated with response <italic toggle="yes">(</italic>Fisher’s exact test, <italic toggle="yes">P</italic> = 0.51 and <italic toggle="yes">P</italic> = 1.0, respectively). Loss of heterozygosity (LOH) in <italic toggle="yes">B2M</italic><sup><xref ref-type="bibr" rid="CR14">14</xref></sup> was found in 9 of 55 (16%) responders and 16 of 65 (25%) progressors (odds ratio (OR) = 0.6) but was not significantly associated with resistance (Fisher’s exact test, <italic toggle="yes">P</italic> = 0.37). LOH in <italic toggle="yes">HLA-A</italic>, <italic toggle="yes">HLA-B</italic> or <italic toggle="yes">HLA-C</italic><sup><xref ref-type="bibr" rid="CR28">28</xref></sup> was not associated with response or resistance to therapy (Fisher’s exact test, <italic toggle="yes">P</italic> = 0.52, <italic toggle="yes">P</italic> = 0.57 and <italic toggle="yes">P</italic> = 0.84, respectively). Confirming previous findings, LOH of <italic toggle="yes">JAK1</italic><sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup> was associated with resistance (OR = 0.33; Fisher’s exact test, <italic toggle="yes">P</italic> = 0.02). Biallelic <italic toggle="yes">CDKN2A</italic> alteration<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> was found in 15 of 55 (27%) responders and 25 of 65 (38%) progressors (OR = 0.6), but was not significant (Fisher’s exact test, <italic toggle="yes">P</italic> = 0.24).</p>
          <p id="Par12">We also performed an unbiased analysis of the association between focal gene amplifications and response to therapy. While no gene amplification was significant after multiple-hypothesis test correction (Extended Data Fig. <xref rid="Fig8" ref-type="fig">3b</xref> and Supplementary Table <xref rid="MOESM4" ref-type="media">3</xref>), amplification of <italic toggle="yes">TAP2</italic>, an integral part of the MHC-I antigen-loading pathway, was found exclusively in responders to therapy (<italic toggle="yes">n</italic> = 6; Fisher’s exact test, <italic toggle="yes">P</italic> = 0.008; Fig. <xref rid="Fig2" ref-type="fig">2d</xref>). <italic toggle="yes">TAP2</italic> is located at 6p21 in a region encoding both MHC-I and MHC-II human leukocyte antigen (HLA) loci, and four out of six <italic toggle="yes">TAP2</italic> amplifications were associated with larger amplifications across the region, while two out of six amplifications were more focal (Extended Data Fig. <xref rid="Fig9" ref-type="fig">4</xref>). Notably, tumors with amplifications in this region encompassing the MHC-I-related <italic toggle="yes">HLA-A</italic>, <italic toggle="yes">HLA-B</italic> and <italic toggle="yes">HLA-C</italic> genes (a region of approximately 1.5 Mb; <italic toggle="yes">n</italic> = 6) were also associated with response to therapy (Fisher’s exact test, <italic toggle="yes">P</italic> = 0.008; Fig. <xref rid="Fig2" ref-type="fig">2e</xref>), with four out of six also having amplifications in <italic toggle="yes">TAP2</italic>. Altogether, eight patients had amplification of either <italic toggle="yes">TAP2</italic> or <italic toggle="yes">HLA-A</italic>, <italic toggle="yes">HLA-B</italic> or <italic toggle="yes">HLA-C</italic> amplification (Fig. <xref rid="Fig2" ref-type="fig">2f</xref> and Extended Data Fig. <xref rid="Fig9" ref-type="fig">4</xref>), and were exclusively responders (Fisher’s exact test, <italic toggle="yes">P</italic> = 0.001).</p>
          <p id="Par13">We then examined the expression of antigen-presentation molecules and their association with response. Interestingly, expression of all 13 MHC-II-associated HLA genes was higher in responders (collective two-sided binomial test, <italic toggle="yes">P</italic> = 0.0002; Fig. <xref rid="Fig2" ref-type="fig">2g</xref>), with four genes (<italic toggle="yes">HLA-DMA</italic>, <italic toggle="yes">HLA-DMB</italic>, <italic toggle="yes">HLA-DOB</italic> and <italic toggle="yes">HLA-DOB</italic>) individually passing a statistical significance threshold (MWW, <italic toggle="yes">P</italic> &lt; 0.05; Supplementary Table <xref rid="MOESM4" ref-type="media">4</xref>). MHC-I antigen-presentation genes all trended toward having higher expression in responders (collective two-sided binomial test, <italic toggle="yes">P</italic> = 0.02; Fig. <xref rid="Fig2" ref-type="fig">2g</xref> and Supplementary Table <xref rid="MOESM4" ref-type="media">4</xref>), but none passed the statistical significance threshold.</p>
          <p id="Par14">To examine pathways differentially enriched in responders versus progressors, we next performed unbiased gene set enrichment analysis (GSEA<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>; <xref rid="Sec9" ref-type="sec">Methods</xref>) using the Hallmark gene sets<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. A total of 24 pathways were enriched (false discovery rate (FDR), <italic toggle="yes">q</italic> &lt; 0.1) in responders, and 5 of the top 6 enriched pathways were immune related, including IFN-γ response, genes involved in allograft rejection, complement, the inflammatory response and interleukin (IL)-6–JAK–STAT3 signaling (Supplementary Table <xref rid="MOESM4" ref-type="media">5</xref>). No pathways were significantly enriched in progressors.</p>
          <p id="Par15">We further evaluated various transcriptomic signatures<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR40">40</xref></sup> that had been proposed and demonstrated in various settings to be associated with response to immunotherapy (<xref rid="Sec9" ref-type="sec">Methods</xref>), but we found no significant differences (<italic toggle="yes">P</italic> &lt; 0.05) in these signatures between responders and progressors within our cohort (Supplementary Table <xref rid="MOESM4" ref-type="media">6</xref>).</p>
          <p id="Par16">Immune infiltrate has been associated with response to immunotherapy across multiple cancer types and immune therapies<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>. We inferred the absolute level of immune infiltrate within each sample using an immune deconvolution algorithm (CIBERSORT<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> using the LM22 signature matrix). We found no significant difference in the total immune infiltrate or abundance of individual immune cell subsets in responders versus progressors (Supplementary Table <xref rid="MOESM4" ref-type="media">7</xref>). We also generated profiles of expression of immune cell subset signatures derived from single-cell analyses<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> and found that the expression of multiple signatures was significantly higher (unadjusted MWW, <italic toggle="yes">P</italic> &lt; 0.05) in responders versus progressors, including for signatures of overall immune infiltrate, T cells, B cells, macrophages, CD8<sup>+</sup> cytotoxic exhausted T cells and CD4<sup>+</sup> exhausted T cells (Supplementary Table <xref rid="MOESM4" ref-type="media">7</xref>). Although the strength of association differed by deconvolution method, both approaches generally agreed on the direction of association, providing evidence for a moderate association of immune infiltrate with the response to anti-PD1 ICB.</p>
        </sec>
        <sec id="Sec5">
          <title>Correlations between molecular features</title>
          <p id="Par17">To understand the relationship between predictors of response, we performed hierarchical clustering of the correlation coefficients between associated predictors (Fig. <xref rid="Fig2" ref-type="fig">2h</xref>). Clustered features are correlated and may reflect the same underlying biology, whereas separate clusters may reflect independent feature categories. A large immune-related cluster with MHC-II- and MHC-I-related subclusters was observed, with a separate independent cluster of mutation- and neoantigen-load-related features, suggesting independent feature categories. Tumor purity was negatively correlated with the immune cluster, suggesting that low tumor purity may be a proxy for higher immune infiltrates within the tumor sample. Other features, including tumor heterogeneity and ploidy, were independent from these two clusters. Extending this analysis to previously hypothesized signatures and Hallmark gene set signatures (Extended Data Fig. <xref rid="Fig10" ref-type="fig">5</xref>), immune activity signatures, including signatures of cytolytic<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> and cytotoxic<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> activity, IFN-γ and T effector cells<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>, immune chemokines<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> and single-cell-derived immune cell signatures<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>, clustered together. A tumor-intrinsic resistance program signature<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>, signatures of T cell dysfunction and exclusion<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> and comparative immune-checkpoint gene expression<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> were distinct from the immune cluster. Overall, these findings suggested that multiple previously hypothesized predictors of ICB response reflect the same underlying biological state and additional independent classes of predictors exist that may provide additional predictive power.</p>
        </sec>
        <sec id="Sec6">
          <title>Previous exposure to anti-CTLA4 ICB</title>
          <p id="Par18">Our cohort contained patients with previous exposure to ipilimumab in anti-CTLA4 ICB (<italic toggle="yes">n</italic> = 60) and patients who were naive to ipilimumab (<italic toggle="yes">n</italic> = 84; Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). Despite the groups having similar response rates (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>), we hypothesized that these two groups might have differential predictors of response and resistance to anti-PD1 ICB. We performed a focused analysis of patients who were treated with ipilimumab and biopsied after treatment (<italic toggle="yes">n</italic> = 44 with WES and <italic toggle="yes">n</italic> = 34 with RNA-seq) versus patients who were naive to ipilimumab (<italic toggle="yes">n</italic> = 84 with WES and <italic toggle="yes">n</italic> = 71 with RNA-seq). A composite, rank-based score of MHC-II HLA expression (single-sample GSEA (ssGSEA)<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>; <xref rid="Sec9" ref-type="sec">Methods</xref>) was higher in responders than in progressors in the overall cohort and the subgroup treated with ipilimumab, but was not significantly different in the subgroup that was naive to ipilimumab (Fig. <xref rid="Fig3" ref-type="fig">3c–e</xref>; MWW, <italic toggle="yes">P</italic> = 0.03, <italic toggle="yes">P</italic> = 0.03 and <italic toggle="yes">P</italic> = 0.31, respectively). We found very similar results in the largest available independent validation cohort<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> with information on previous ipilimumab treatment (Fig. <xref rid="Fig3" ref-type="fig">3f–h</xref>), although the difference was not significant in this smaller cohort (<italic toggle="yes">n</italic> = 32 patients, 15 of whom were treated with ipilimumab and 17 of whom were naive for ipilimumab).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>Differential predictors of response and progression in ipilimumab-treated tumors versus ipilimumab-naive tumors.</title><p><bold>a</bold>, Timeline showing when sequenced biopsies were obtained from tumors that were treated with ipilimumab or naive to ipilimumab in the course of therapy. Subsequent analyses focused on comparing tumor biopsies obtained after ipilimumab treatment (<italic toggle="yes">n</italic> = 45 WES, <italic toggle="yes">n</italic> = 34 RNA-seq) to ipilimumab-naive tumor biopsies (<italic toggle="yes">n</italic> = 84 WES, <italic toggle="yes">n</italic> = 74 RNA-seq). <bold>b</bold>, Best RECIST response by ipilimumab pretreatment status. There was no difference between the distribution of responses in naive (<italic toggle="yes">n</italic> = 84) and pretreated (<italic toggle="yes">n</italic> = 60) patients (two-sided chi-squared test, <italic toggle="yes">P</italic> = 0.44; degrees of freedom (d.f.) = 3). <bold>c</bold>, ssGSEA of MHC-II HLA genes (<xref rid="Sec9" ref-type="sec">Methods</xref>) in responders (<italic toggle="yes">n</italic> = 47 patients) versus progressors (<italic toggle="yes">n</italic> = 56 patients) in the overall cohort. MHC-II scores were higher in responders than in progressors (two-sided MWW, <italic toggle="yes">P</italic> = 0.03). <bold>d</bold>, ssGSEA of MHC-II HLA genes in responders versus progressors in the post-ipilimumab-treatment subgroup. MHC-II scores were higher in responders (<italic toggle="yes">n</italic> = 11 patients) than in progressors (<italic toggle="yes">n</italic> = 16 patients; two-sided MWW, <italic toggle="yes">P</italic> = 0.03). <bold>e</bold>, ssGSEA of MHC-II HLA genes in responders (<italic toggle="yes">n</italic> = 31 patients) versus progressors (<italic toggle="yes">n</italic> = 34 patients) in the ipilimumab-naive subgroup. There was no significant difference in MHC-II scores between responders and progressors (two-sided MWW, <italic toggle="yes">P</italic> = 0.31). <bold>f</bold>, MHC-II HLA gene set scores (ssGSEA) in responders (<italic toggle="yes">n</italic> = 10 patients) versus progressors (<italic toggle="yes">n</italic> = 22 patients) in a validation cohort (<xref rid="Sec9" ref-type="sec">Methods</xref>; two-sided MWW, <italic toggle="yes">P</italic> = 0.34). <bold>g</bold>, MHC-II HLA gene set scores (ssGSEA) in responders (<italic toggle="yes">n</italic> = 4 patients) versus progressors (<italic toggle="yes">n</italic> = 11 patients) in the ipilimumab-treated subgroup of a validation cohort (two-sided MWW, <italic toggle="yes">P</italic> = 0.10). <bold>h</bold>, MHC-II HLA gene set scores (ssGSEA) in responders (<italic toggle="yes">n</italic> = 6 patients) versus progressors (<italic toggle="yes">n</italic> = 11 patients) in the ipilimumab-naive subgroup of a validation cohort (two-sided MWW, <italic toggle="yes">P</italic> = 0.80). <bold>i</bold>, Selected Cancer Hallmark gene sets (GSEA) enriched in responders versus progressors in the overall (<italic toggle="yes">n</italic> = 47 responders and 56 progressors), post-ipilimumab-treatment (<italic toggle="yes">n</italic> = 11 responders and 16 progressors), and ipilimumab-naive (<italic toggle="yes">n</italic> = 31 responders and 34 progressors) subgroups of our discovery cohort. IFN-γ and IFN-α response pathways were enriched in responders in the overall (FDR, <italic toggle="yes">q</italic> &lt; 0.001 and <italic toggle="yes">q</italic> = 0.02, respectively) and ipilimumab-treated (<italic toggle="yes">q</italic> &lt; 0.001, both) subgroups but not in the ipilimumab-naive subgroups (<italic toggle="yes">q</italic> = 0.13 and <italic toggle="yes">q</italic> = 0.997, respectively) in the discovery cohort (empiric, <italic toggle="yes">P</italic> = 0.183 and <italic toggle="yes">P</italic> = 0.18, respectively for the difference in <italic toggle="yes">q</italic> values between the subgroups; <xref rid="Sec9" ref-type="sec">Methods</xref>). <bold>j</bold>, Selected Cancer Hallmark gene sets (GSEA) enriched in responders versus progressors in the overall, post-ipilimumab-treatment and ipilimumab-naive subgroups in an independent validation cohort. IFN-γ and IFN-α response pathways were enriched in responders in the overall (FDR, <italic toggle="yes">q</italic> &lt; 0.0001 and <italic toggle="yes">q</italic> = 0.0034, respectively) and ipilimumab-treated (<italic toggle="yes">q</italic> &lt; 0.0001, both) subgroups but not in the ipilimumab-naive subgroup (<italic toggle="yes">q</italic> = 0.87 and <italic toggle="yes">q</italic> = 0.03 (enriched in progressors), respectively) in the discovery cohort. Pathways favoring enrichment in progressors (as opposed to responders) are visualized here with an FDR <italic toggle="yes">q</italic> value of 1. All Hallmark pathways and their GSEA enrichment scores are shown in Supplementary Table <xref rid="MOESM4" ref-type="media">5</xref>. Boxplots: box limits indicate the IQR (25th to 75th percentile), with a center line indicating the median. Whiskers show the value ranges up to 1.5 × IQR above the 75th or below the 25th percentile, with outliers beyond those ranges shown as individual points. *<italic toggle="yes">P</italic> &lt; 0.05, **<italic toggle="yes">P</italic> &lt; 0.01, ***<italic toggle="yes">P</italic> &lt; 0.001. NS, not significant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d30e2196" position="float" orientation="portrait" xlink:href="41591_2019_654_Fig3_HTML.jpg"/></fig></p>
          <p id="Par19">We next examined the association of TMB, purity, ploidy and heterogeneity with response stratified by previous ipilimumab therapy (Extended Data Fig. <xref rid="Fig11" ref-type="fig">6a</xref>). Unlike previous studies<sup><xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR45">45</xref></sup>, we found no specific association of a higher TMB with response in the ipilimumab-naive versus ipilimumab-treated subgroup (MWW, <italic toggle="yes">P</italic> = 0.15, both). However, higher heterogeneity and lower ploidy were associated with progressors only in the ipilimumab-naive subgroup (MWW, <italic toggle="yes">P</italic> = 0.06 and <italic toggle="yes">P</italic> = 0.004, respectively).</p>
          <p id="Par20">We analyzed the differential expression of specific immune-related genes in responders versus progressors in ipilimumab-treated and ipilimumab-naive subgroups and found that higher expression of various immune-related pathways distinguished responders from progressors in ipilimumab-treated but not ipilimumab-naive subgroups (all <italic toggle="yes">P</italic> values are unadjusted). Examples included the leukocyte chemoattractants <italic toggle="yes">CXCL9</italic> and <italic toggle="yes">CXCL10</italic> and their receptor <italic toggle="yes">CXCR3</italic> (MWW, <italic toggle="yes">P</italic> = 0.05, <italic toggle="yes">P</italic> = 0.08 and <italic toggle="yes">P</italic> = 0.02, respectively, in the ipilimumab-treated subgroup), <italic toggle="yes">CD3D</italic> (MWW, <italic toggle="yes">P</italic> = 0.02), B cell markers <italic toggle="yes">CD19</italic> (MWW, <italic toggle="yes">P</italic> = 0.04) and <italic toggle="yes">CD20</italic> (<italic toggle="yes">MS4A1</italic>; MWW, <italic toggle="yes">P</italic> = 0.002) and macrophage marker <italic toggle="yes">CD163</italic> (MWW, <italic toggle="yes">P</italic> = 0.03). Interestingly, <italic toggle="yes">CD4</italic>, <italic toggle="yes">FOXP3</italic>
<italic toggle="yes">and CTLA4</italic> also followed this pattern of higher expression in responders in the ipilimumab-treated subgroup <italic toggle="yes">(</italic>MWW, <italic toggle="yes">P</italic> = 0.06, <italic toggle="yes">P</italic> <italic toggle="yes">=</italic> 0.06 and <italic toggle="yes">P</italic> = 0.008, respectively), but <italic toggle="yes">CD8A</italic> and <italic toggle="yes">CD8B</italic> had less evidence of association with response in either ipilimumab-treated (MWW, <italic toggle="yes">P</italic> = 0.17 and <italic toggle="yes">P</italic> <italic toggle="yes">=</italic> 0.27, respectively) or ipilimumab-naive (MWW, <italic toggle="yes">P</italic> = 0.93 and <italic toggle="yes">P</italic> <italic toggle="yes">=</italic> 0.49, respectively) subgroups. Expression of <italic toggle="yes">TAP2</italic> was higher (MWW, <italic toggle="yes">P</italic> = 0.02) in responders than in progressors in the ipilimumab-treated subgroup but not in the ipilimumab-naive subgroup (MWW, <italic toggle="yes">P</italic> = 0.98). In contrast, <italic toggle="yes">TGFB2</italic> expression was higher in progressors in the ipilimumab-naive subgroup (MWW, <italic toggle="yes">P</italic> = 0.002) but not in the ipilimumab-treated subgroup (MWW, <italic toggle="yes">P</italic> = 0.43). The complete set of gene expression comparisons in the overall, ipilimumab-treated and ipilimumab-naive cohorts is in Supplementary Table <xref rid="MOESM4" ref-type="media">4</xref>.</p>
          <p id="Par21">We then repeated GSEA to examine the pathways differentially enriched in responders versus progressors between ipilimumab-treated and ipilimumab-naive subgroups. The most differentially enriched pathways were related to immune response: the IFN-γ and IFN-α responses were significantly enriched in responders in the ipilimumab-treated subgroup (FDR, <italic toggle="yes">q</italic> &lt; 0.0001, both), but not in the ipilimumab-naive subgroup (FDR, <italic toggle="yes">q</italic> = 0.13 and <italic toggle="yes">q</italic> = 0.996, respectively; Fig. <xref rid="Fig3" ref-type="fig">3i</xref>). Using permutation testing (<xref rid="Sec9" ref-type="sec">Methods</xref>), we found a nonsignificant empiric <italic toggle="yes">P</italic> value of 0.183 and 0.18, respectively, for this difference in enriched pathways in these subgroups in our discovery cohort. However, we repeated the analysis in an independent validation cohort<sup><xref ref-type="bibr" rid="CR46">46</xref></sup> and found similar results (Fig. <xref rid="Fig3" ref-type="fig">3j</xref>). Complete GSEA results are provided in Supplementary Table <xref rid="MOESM4" ref-type="media">5</xref>.</p>
          <p id="Par22">To further dissect the impact of MHC-II expression on patient response, we stratified the cohort into patients with high and low MHC-II expression (ssGSEA, median split). In the overall cohort, low MHC-II expression was associated with primary resistance (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>; Fisher’s exact test, <italic toggle="yes">P</italic> = 0.01; OR = 2.9, 95% confidence interval (CI) 1.3–6.5), but this association was largely driven by the ipilimumab-treated subgroup (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>; Fisher’s exact test, <italic toggle="yes">P</italic> = 0.02; OR = 9.9, 95% CI 1.5–63.7), with a nonsignificant association in the ipilimumab-naive subgroup (Fig. <xref rid="Fig4" ref-type="fig">4c</xref>; Fisher’s exact test, <italic toggle="yes">P</italic> = 0.32; OR = 1.9, 95% CI 0.7–5.1). A formal interaction test of previous ipilimumab treatment status with MHC-II expression for predicting response was consistent with a subgroup-specific effect of low MHC-II expression on the ipilimumab-experienced subgroup (OR = 0.20, 95% CI 0.02–1.64), although this was nonsignificant (<italic toggle="yes">P</italic> = 0.13) in this small cohort.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>Progression versus response by immune infiltrate and MHC-II HLA expression stratified by ipilimumab treatment.</title><p><bold>a</bold>, Proportion of responders versus progressors in subgroups with high and low MHC-II HLA score (ssGSEA; divided by the median). Overall, a high MHC-II HLA score was associated with higher response (MHC-II high: <italic toggle="yes">n</italic> = 29 responders and 20 progressors; MHC-II low: <italic toggle="yes">n</italic> = 18 responders and 36 progressors; two-sided Fisher’s exact test, <italic toggle="yes">P</italic> = 0.01; OR = 2.9, 95% CI 1.3–6.5). <bold>b</bold>, As in <bold>a</bold> but in the ipilimumab-treated subgroup. Tumors with low MHC-II HLA score (ssGSEA) were associated with PD (MHC-II high: <italic toggle="yes">n</italic> = 9 responders and 5 progressors; MHC-II low: <italic toggle="yes">n</italic> = 2 responders and 11 progressors; two-sided Fisher’s exact test, <italic toggle="yes">P</italic> = 0.02; OR = 9.9, 95% CI 1.5–63.7). <bold>c</bold>, As in <bold>a</bold> but in the ipilimumab-naive subgroup. There was no significant difference between tumors with high and low MHC-II HLA scores (ssGSEA; MHC-II high: <italic toggle="yes">n</italic> = 18 responders and 14 progressors; MHC-II low: <italic toggle="yes">n</italic> = 13 responders and 19 progressors; two-sided Fisher’s exact <italic toggle="yes">test, P</italic> = 0.32; OR = 1.9, 95% CI 0.7–5.1). <bold>d</bold>, Proportion of responders versus progressors in subgroups with high and low immune infiltrate scores (divided by the median). Overall, there was no statistically significant difference in the proportion of responders versus progressors in tumors with high versus low immune infiltrate (infiltrate high: <italic toggle="yes">n</italic> = 27 responders and 24 progressors; infiltrate low: <italic toggle="yes">n</italic> = 20 responders and 32 progressors; two-sided Fisher’s exact test, <italic toggle="yes">P</italic> = 0.17; OR = 1.8, 95% CI 0.8–3.9). <bold>e</bold>, As in <bold>d</bold> but in the ipilimumab-treated subgroup. Tumors with low immune infiltrate scores were strongly associated with PD (infiltrate high: <italic toggle="yes">n</italic> = 10 responders and 7 progressors; infiltrate low: <italic toggle="yes">n</italic> = 1 responder and 9 progressors; two-sided Fisher’s exact test, <italic toggle="yes">P</italic> = 0.02; OR = 12.9, 95% CI 1.3–125.8). <bold>f</bold>, As in <bold>d</bold> but in the ipilimumab-naive subgroup. There was no statistically significant difference between tumors with high and low immune infiltrate scores (infiltrate high: <italic toggle="yes">n</italic> = 14 responders and 15 progressors; infiltrate low: <italic toggle="yes">n</italic> = 17 responders and 18 progressors; two-sided Fisher’s exact test, <italic toggle="yes">P</italic> = 1.0; OR = 0.99, 95% CI 0.4–2.6). <bold>g</bold>, Schematic of the hypothesized effect of ipilimumab treatment on immune response as a predictor of subsequent response to anti-PD1 ICB. Tumors that were treated with ipilimumab but failed to have an immune response or infiltrate in the tumor microenvironment were strongly predicted to have intrinsic resistance to anti-PD1 ICB. However, having an immune response did not guarantee a subsequent response to anti-PD1 ICB. In ipilimumab-naive tumors, neither the presence nor the absence of immune infiltrate was a good predictor of anti-PD1 ICB response.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d30e2498" position="float" orientation="portrait" xlink:href="41591_2019_654_Fig4_HTML.jpg"/></fig></p>
          <p id="Par23">A similar analysis of estimated total immune infiltrate levels<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> (with tumors split by the median into high and low groups) showed that low immune infiltrate was significantly associated with intrinsic resistance in the ipilimumab-treated subgroup (Fig. <xref rid="Fig4" ref-type="fig">4e</xref>; Fisher’s exact test, <italic toggle="yes">P</italic> = 0.02; OR = 12.9, 95% CI 1.3–125.8), but not in the ipilimumab-naive subgroup (Fig. <xref rid="Fig4" ref-type="fig">4f</xref>; Fisher’s exact test, <italic toggle="yes">P</italic> = 1.00; OR = 0.99, 95% CI 0.4–2.6) or overall cohort (Fig. <xref rid="Fig4" ref-type="fig">4d</xref>; Fisher’s exact test, <italic toggle="yes">P</italic> = 0.17; OR = 1.8, 95% CI 0.8–3.9), indicating a subgroup-specific association in the ipilimumab-experienced subgroup of low immune infiltrate with resistance to therapy (OR = 0.08, 95% CI 0.007–0.97; <italic toggle="yes">P</italic> = 0.047).</p>
          <p id="Par24">Taken together, these findings suggest that evidence of immune response in the tumor microenvironment at the time of progression following anti-CTLA4 ICB is a necessary but not sufficient marker for response to anti-PD1 ICB therapy; patients without immune response to anti-CTLA4 ICB are very likely to also be intrinsically resistant to anti-PD1 ICB, highlighting a high-risk and poor-prognosis subgroup of patients (Fig. <xref rid="Fig4" ref-type="fig">4g</xref>).</p>
        </sec>
        <sec id="Sec7">
          <title>Integrative predictive modeling of primary resistance</title>
          <p id="Par25">Patients with primary resistance to anti-PD1 ICB have poor survival (Extended Data Fig. <xref rid="Fig12" ref-type="fig">7</xref>), and the ability to predict these patients would enable individualized management regimens (for example combination ICB) to improve outcomes. Thus, we set out to develop parsimonious predictive models integrating clinical, genomic and transcriptomic features to predict PD (primary resistance) versus non-PD (CR, PR, SD and MR) and developed separate predictive models in ipilimumab-treated and ipilimumab-naive subgroups.</p>
          <p id="Par26">In the ipilimumab-treated group (<italic toggle="yes">n</italic> = 34 with WES and RNA-seq), there were 16 patients who had PD and 18 who had non-PD. Using a forward-selection approach to choose the features of a parsimonious predictive model (<xref rid="Sec9" ref-type="sec">Methods</xref>), low MHC-II HLA expression was most strongly predictive of PD (Fig. <xref rid="Fig5" ref-type="fig">5a</xref>) and was correlated with MHC-I HLA, IFN-α and IFN-γ response pathway scores. In the final multivariate model, high MHC-II expression, low lactate dehydrogenase (LDH; below the median of 247 U l<sup>−1</sup>) and the presence of lymph node metastases were independent predictors of non-PD (<italic toggle="yes">P</italic> = 0.03, <italic toggle="yes">P</italic> = 0.02 and <italic toggle="yes">P</italic> = 0.04, respectively, Supplementary Table <xref rid="MOESM4" ref-type="media">8</xref> and Extended Data Fig. <xref rid="Fig13" ref-type="fig">8a,c</xref>), and the model had an area under the curve (AUC) of 0.90 in our discovery cohort (fivefold cross-validation mean AUC = 0.83; empiric <italic toggle="yes">P</italic> &lt; 0.001; Fig. <xref rid="Fig5" ref-type="fig">5b</xref>, Extended Data Fig. <xref rid="Fig13" ref-type="fig">8f</xref> and <xref rid="Sec9" ref-type="sec">Methods</xref>). Notably, TMB did not significantly improve model fit (log-likelihood ratio, <italic toggle="yes">P</italic> = 0.10), was not an independently predictive feature (<italic toggle="yes">P</italic> = 0.18) and did not meet Bayesian information criteria (BIC; Extended Data Fig. <xref rid="Fig13" ref-type="fig">8c</xref>) when added to the model.<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><title>Integrative predictive modeling of intrinsic resistance to anti-PD1 ICB.</title><p><bold>a</bold>, CoMut plot showing the relationship between response and predictive features in the ipilimumab-treated subgroup. Each column represents a patient, and the top row indicates whether the patient had PD (intrinsic resistance) or non-PD (CR, PR, SD or MR) as the best response. Patients are sorted by MHC-II HLA score, which was the most predictive feature and was correlated with MHC-I and IFN response pathway scores. MHC-II HLA, LDH at treatment initiation and the presence of lymph node metastases (LN met) were features used for our logistic regression model, chosen using forward selection (<xref rid="Sec9" ref-type="sec">Methods</xref>). <bold>b</bold>, A receiver–operator characteristic (ROC) curve for our predictive model for ipilimumab-treated tumors (<italic toggle="yes">n</italic> = 34 patients) using MHC-II HLA, LDH and lymph node metastases as features. The AUC was 0.9, and the log-likelihood ratio was <italic toggle="yes">P</italic> = 0.0003. The fivefold cross-validation mean AUC was 0.83. <bold>c</bold>, CoMut plot showing the relationship between response and predictive features in the ipilimumab-naive subgroup. Each column represents a patient, and the top row indicates whether the patient had PD (intrinsic resistance) or non-PD as the best response. Patients are sorted by tumor heterogeneity (top), tumor ploidy (middle) and tumor purity (bottom), which were the three features chosen in our predictive model (<xref rid="Sec9" ref-type="sec">Methods</xref>). Purity, ploidy and heterogeneity were independent predictors in the multivariate model (Supplementary Table <xref rid="MOESM4" ref-type="media">9</xref>). <bold>d</bold>, The ROC curve for our predictive model for ipilimumab-naive tumors (<italic toggle="yes">n</italic> = 84 tumors) using heterogeneity, purity and ploidy as features. The AUC was 0.77, and the log-likelihood ratio was <italic toggle="yes">P</italic> = 0.0003. The average tenfold cross-validation mean AUC was 0.73. <bold>e</bold>, Survival (PFS and OS as indicated) stratified by high versus low predictive model score (split by the median) in ipilimumab-treated tumors in our discovery cohort. Tumors with high scores had worse PFS and OS (two-sided KM log-rank test, <italic toggle="yes">P</italic> = 0.0001 and <italic toggle="yes">P</italic> = 0.001, respectively). <bold>f</bold>, Survival (PFS and OS as indicated) stratified by high versus low predictive model score (split by the median) in ipilimumab-naive tumors in our discovery cohort. Tumors with high scores had worse PFS and OS (two-sided KM log-rank test, <italic toggle="yes">P</italic> = 0.003 and <italic toggle="yes">P</italic> = 6.3 × 10<sup>−5</sup>, respectively).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d30e2657" position="float" orientation="portrait" xlink:href="41591_2019_654_Fig5_HTML.jpg"/></fig></p>
          <p id="Par27">In the ipilimumab-naive group, there were 34 patients with PD and 41 with non-PD. In the multivariate predictive model, higher heterogeneity, lower ploidy and higher purity were independently predictive of PD (<italic toggle="yes">P</italic> = 0.025, <italic toggle="yes">P</italic> = 0.014 and <italic toggle="yes">P</italic> = 0.046, respectively; Fig. <xref rid="Fig5" ref-type="fig">5c</xref>, Supplementary Table <xref rid="MOESM4" ref-type="media">9</xref> and Extended Data Fig. <xref rid="Fig13" ref-type="fig">8b,d</xref>), with an AUC of 0.77 (tenfold cross-validation mean AUC of 0.73; empiric <italic toggle="yes">P</italic> = 0.036; Fig. <xref rid="Fig5" ref-type="fig">5d</xref>, Extended Data Fig. <xref rid="Fig13" ref-type="fig">8e</xref> and <xref rid="Sec9" ref-type="sec">Methods</xref>). TMB did not significantly improve the model fit (log-likelihood ratio test, <italic toggle="yes">P</italic> = 0.63), was not an independently predictive feature (<italic toggle="yes">P</italic> = 0.63) and did not meet BIC criteria (Extended Data Fig. <xref rid="Fig13" ref-type="fig">8d</xref>) when added to this multivariate model. Further, each model’s performance was specific to its subgroup (<italic toggle="yes">P</italic> = 0.004 and <italic toggle="yes">P</italic> = 0.018 for the interaction between ipilimumab-experienced and ipilimumab-naive model scores, respectively, and previous ipilimumab therapy). Each model had poor performance when applied to the opposing subgroup (AUC = 0.49 and AUC = 0.54, respectively; Extended Data Fig. <xref rid="Fig14" ref-type="fig">9a,b</xref>), suggesting that previous ipilimumab treatment status may stratify the appropriate predictors and predictive models to be applied in these subgroups.</p>
          <p id="Par28">We attempted to validate our models in independent cohorts but were limited by a lack of publicly available cohorts with all the molecular features and relevant clinical data on previous ipilimumab therapy and biopsy timing used in our integrated model. In a limited validation, we tested predictive models incorporating individual features where data were available in an independent validation cohort<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> (<xref rid="Sec9" ref-type="sec">Methods</xref>), and found concordant predictions of primary resistance with low MHC-II HLA expression in ipilimumab-treated tumors and higher heterogeneity in ipilimumab-naive tumors (Extended Data Fig. <xref rid="Fig15" ref-type="fig">10</xref>), although neither of these predictors was significant in this small cohort (empiric <italic toggle="yes">P</italic> = 0.21 and <italic toggle="yes">P</italic> = 0.066, respectively; <xref rid="Sec9" ref-type="sec">Methods</xref>).</p>
          <p id="Par29">In an exploratory analysis, we predicted PD in response to anti-PD1 ICB in tumors where the tumor biopsy was taken before ipilimumab treatment (<italic toggle="yes">n</italic> = 15; Fig. <xref rid="Fig3" ref-type="fig">3a</xref>) using our ipilimumab-naive predictive model. Of the eight tumors with PD in response to anti-PD1 ICB, five had the highest model scores (Extended Data Fig. <xref rid="Fig14" ref-type="fig">9c</xref>), with an overall AUC of 0.71. Interestingly, of the three poorly discriminated tumors with low model scores but PD responses, one (patient 82) was from a brain metastasis and one (patient 80) was an acral melanoma.</p>
          <p id="Par30">Finally, splitting the cohort into subsets with high and low model scores (split by the median), we found large differences in OS and PFS in both the ipilimumab-treated subgroup (Fig. <xref rid="Fig5" ref-type="fig">5e</xref>; median PFS: 38.1 months versus 2.8 months, log-rank <italic toggle="yes">P</italic> = 0.0001; median OS: unreached versus 9.0 months, log-rank <italic toggle="yes">P</italic> = 0.001) and ipilimumab-naive subgroup (Fig. <xref rid="Fig5" ref-type="fig">5f</xref>; median PFS: 24.7 months versus 3.1 months, log-rank <italic toggle="yes">P</italic> = 0.005; median OS: unreached versus 15.0 months, log-rank <italic toggle="yes">P</italic> &lt; 0.0001).</p>
        </sec>
      </sec>
      <sec id="Sec8" sec-type="discussion">
        <title>Discussion</title>
        <p id="Par31">In this study, we analyzed a uniformly clinically annotated cohort of patients with advanced melanoma treated with anti-PD1 ICB monotherapy for whom WES and RNA-seq data were available. While we observed an association between response and TMB, this observation was confounded by disease subtype, strongly suggesting that TMB cannot be applied generically across melanoma subtypes as a predictive biomarker for anti-PD1 ICB.</p>
        <p id="Par32">Beyond TMB, we found that MHC-II expression, tumor heterogeneity, purity and ploidy were associated with ICB response. In two previous studies<sup><xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR48">48</xref></sup>, MHC-II expression on tumor cells by immunohistochemistry was found to be predictive for response to anti-PD1 ICB and was hypothesized to represent a subset of tumors that could stimulate CD4<sup>+</sup> helper T cell or cytotoxic activity. Consistent with this hypothesis, we found that MHC-II transcriptomic expression was correlated with expression of <italic toggle="yes">CD4</italic> and the cytolytic molecules <italic toggle="yes">PRF1</italic> and <italic toggle="yes">GZMA</italic> in our cohort. However, whether MHC-II expression represents expression on tumor cells or antigen-presenting cells within the tumor microenvironment cannot be determined from our bulk transcriptome data, and whether the association of PD1 ICB response with MHC-II expression is limited to tumor-cell-specific MHC-II expression is unclear. Notably, CD8<sup>+</sup> T cell markers were not higher in responders versus progressors in our cohort, and although MHC-II, MHC-I, IFN-γ and IFN-α response pathway expression was correlated, MHC-II expression was the best predictor of response in our cohort. Further, we found evidence for the involvement of other immune compartments (for example, B cell markers enriched in ipilimumab-experienced responders) in ICB response, consistent with data from a recent trial demonstrating higher B cell infiltrate in responders to neoadjuvant immunotherapy<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>, although the specific cell types, functional states and tumor immune interactions are not yet well characterized.</p>
        <p id="Par33">Tumor heterogeneity (the proportion of subclonal mutations) has previously been associated with poor prognosis across multiple tumor types and therapies<sup><xref ref-type="bibr" rid="CR49">49</xref>–<xref ref-type="bibr" rid="CR51">51</xref></sup>. High heterogeneity suggests a highly mutagenic disease and a high degree of subclonality, with a higher likelihood of preexisting or rapidly evolving resistant clones. Interestingly, in our cohort, four patients had a very high TMB with an alkylating chemotherapy mutational signature (and known previous alkylating chemotherapy); low tumor heterogeneity distinguished the two responders from the two nonresponders (with SD and PD as the best response), who had high tumor heterogeneity with a majority of subclonal mutations. This association has also been observed in dacarbazine-experienced patients with melanoma treated with anti-CTLA4 ICB<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>, suggesting that tumor heterogeneity may be significantly correlated with ICB resistance.</p>
        <p id="Par34">In our cohort, higher ploidy and lower purity were associated with ICB response, but the biological basis of these relationships is unclear. Genome doubling events are common in cancer and may accelerate genome evolution by increasing the tolerance of genome instability<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>, and higher aneuploidy has been associated with a worse response to ICB<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. However, whether genome doubling (and higher ploidy) is also associated with increased immunogenicity is unclear. Purity is negatively correlated with expression of markers of immune response and may be a proxy for the level of immune response in the tumor microenvironment in this setting rather than an artifact of tumor sample processing. However, tumor purity may also reflect differences in tumor biology leading to intrinsic resistance.</p>
        <p id="Par35">Notably, we found that previous exposure to anti-CTLA4 ICB affected the predictors of response to anti-PD1 ICB, although patients with and without exposure had similar response rates to anti-PD1 ICB. Immune-related markers are strongly enriched in responders compared to progressors with previous ipilimumab exposure, but this relationship is less clear in ipilimumab-naive patients. Specifically, post-ipilimumab tumors with poor immune response at progression were resistant to further anti-PD1 ICB, whereas ipilimumab-naive immune-poor and immune-infiltrated tumors were similarly likely to respond to anti-PD1 ICB. Whether anti-CTLA4 ICB induces or, alternatively, reveals an immune-resistant state in a subset of melanomas is an important question that deserves further evaluation. Further, cross-resistance to sequential ICB may also predict resistance to simultaneous combination ICB; this hypothesis should be evaluated in an appropriate cohort.</p>
        <p id="Par36">Building on these findings, we constructed predictive models integrating clinical, genomic and transcriptomic characteristics to identify patients with melanoma with intrinsic resistance to anti-PD1 ICB. Integrating multiple clinical and molecular features resulted in superior discrimination compared to models with any single feature or modality. In patients treated with ipilimumab, low MHC-II expression and high LDH predicted intrinsic resistance, whereas lymph node metastasis predicted improved response to therapy. MHC-II<sup><xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR48">48</xref></sup> and LDH<sup><xref ref-type="bibr" rid="CR53">53</xref></sup> have previously been implicated in predicting anti-PD1 responsiveness. Lymph node metastases might provide a reservoir of tumor-specific immune cells, facilitating their activation by physiologic lymph node function; recent experimental data in a murine model suggests that lymph node metastases are necessary for PD1 response<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>, and recent clinical data showing greater tumor-resident T cell clone response to neoadjuvant compared to adjuvant immunotherapy further supports this hypothesis<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. Similarly, integrating tumor heterogeneity, ploidy and purity for ipilimumab-naive disease resulted in a higher AUC than was obtained with any single-feature model alone. Beyond predicting response, these parsimonious models strongly stratified patients by PFS and OS, suggesting potential clinical applicability in identifying patients at high and low risk.</p>
        <p id="Par37">These findings will require validation in independent and larger cohorts; at the time of our study, limited data were publicly available where molecularly sequenced tumors with previous treatment data and all relevant clinical parameters were available for validation. Further, heterogeneity in sequencing approaches and data normalization between cohorts hindered our ability to develop standardized features to create and validate models. However, our results highlight the value of integrating rich clinical data with molecular tumor characterization and the need to generate such multimodal data.</p>
      </sec>
      <sec id="Sec9">
        <title>Methods</title>
        <sec id="Sec10">
          <title>Patient cohort and clinical end points</title>
          <p id="Par38">Patients were identified in databases of participating sites. For enrollment, patients were required to have advanced melanoma and to have received PD1 blockade as a palliative treatment. Tissue obtained before PD1 blockade was required for enrollment and was collected during routine medical care. Clinicopathological and demographic data were collected from patient records locally and are shown in Table <xref rid="Tab1" ref-type="table">1</xref>. Age, stage and ECOG performance status were documented before the first application of anti-PD1 ICB. LDH was measured within 28 d of the first application of nivolumab or pembrolizumab. OS was defined as the time between the first application of anti-PD1 ICB and the date of death (any cause). For subjects without documentation of death, OS was censored on the last date the patient was known to be alive. BOR to anti-PD1 ICB was assessed according to RECIST criteria v.1.1 by the participating sites. Patients achieving CR or PR as BOR were grouped as responders, whereas patients showing PD as the best response were referred to as progressors. Patients were classified as MR when achieving unequivocal responses in individual existing lesions but also progression in others or new lesions. PFS was defined as the time between the first application of anti-PD1 ICB and the date of documented disease progression. For patients without documentation of progression, PFS was censored on the last date the patient was known to be without progression.</p>
          <p id="Par39">This retrospective study and associated informed consent procedures were approved by the central Ethics Committee (EC) of the University Hospital Essen (12-5152-BO and 11-4715). Approval by the local EC was obtained by investigators if required by local regulations.</p>
        </sec>
        <sec id="Sec11">
          <title>Samples</title>
          <p id="Par40">Samples were collected retrospectively and obtained by excision or biopsy of melanoma tissue, collected locally at the participating sites and provided formalin-fixed and paraffin-embedded (FFPE). Samples were collected between January 2013 and June 2016. The median time from biopsy to initiation of anti-PD1 blockade was 2.1 months with 90% of samples being collected 6 months before the first application of nivolumab or pembrolizumab. All biopsies were from metastatic sites, with the exception of eight biopsies; seven were from a primary lesion and one was from a recurrence at a primary site, representing less than 6% of the overall cohort.</p>
        </sec>
        <sec id="Sec12">
          <title>Whole-exome and whole-transcriptome sequencing</title>
          <p id="Par41">DNA extraction, whole exome library preparation and sequencing were performed for samples as previously described<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>. Slides were cut from FFPE blocks and macrodissected for tumor-enriched tissue. Paraffin was removed from FFPE sections and cores using CitriSolv (Fisher Scientific), followed by ethanol washes and tissue lysis overnight at 56 °C. Samples were then incubated at 90 °C to remove DNA cross links. Extraction of DNA, and, when possible, RNA was performed using the QIAGEN AllPrep DNA/RNA mini kit (51306). Germline DNA was obtained from peripheral blood mononuclear cells and adjacent normal tissue.</p>
          <p id="Par42">Whole-exome capture libraries were constructed from 100 ng of DNA from tumor and normal tissue after sample shearing, end repair and phosphorylation and ligation to barcoded sequencing adaptors. Ligated DNA was size selected for lengths of 200–350 bp and subjected to exonic hybrid capture using Illumina library preps. The sample was multiplexed and sequenced using Illumina HiSeq technology. The Illumina exome sequencing approach uses Illumina’s in-solution DNA-probe-based hybrid selection method that applies principles similar to those of Broad Institute–Agilent Technologies’ in-solution RNA-probe-based hybrid selection method<sup><xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup> to generate Illumina exome sequencing libraries.</p>
          <p id="Par43">Total RNA was assessed for quality using the Caliper LabChip GX2. The percentage of fragments with a size greater than 200 nucleotides (DV200) was calculated using software. An aliquot of 200 ng of RNA was used as the input for first-strand cDNA synthesis using Illumina’s TruSeq RNA Access Library Prep kit. Synthesis of the second strand of cDNA was followed by indexed adaptor ligation. Subsequent PCR amplification enriched for adaptor-ligated fragments. The amplified libraries were quantified using an automated PicoGreen assay.</p>
          <p id="Par44">A total of 200 ng of each cDNA library, not including controls, was combined into four-plex pools. Capture probes that target the exome were added and hybridized for the recommended time. Following hybridization, streptavidin magnetic beads were used to capture the library-bound probes from the previous step. Two wash steps effectively removed any nonspecifically bound products. These same hybridization, capture and wash steps were repeated to assure high specificity. A second round of amplification enriched the captured libraries. After enrichment the libraries were quantified with qPCR using the KAPA Library Quantification kit for Illumina sequencing platforms and were then pooled at an equimolar ratio. The entire process was in a 96-well format and all pipetting was performed using Agilent Bravo or Hamilton Starlet.</p>
          <p id="Par45">Pooled libraries were normalized to 2 nM and denatured using 0.2 N NaOH before sequencing. Flowcell cluster amplification and sequencing were performed according to the manufacturer’s protocols using either the HiSeq 2000 v.3 or HiSeq 2500. Each run generated 76-bp paired-end reads with a dual eight-base index barcode. Data were analyzed using the Broad Picard Pipeline, which includes demultiplexing and data aggregation.</p>
        </sec>
        <sec id="Sec13">
          <title>Quality control and variant calling</title>
          <p id="Par46">Initial exome sequence data processing and analysis were performed using pipelines at the Broad Institute. After alignment from the Broad Picard Pipeline, BAM files were uploaded into the Firehose infrastructure (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://software.broadinstitute.org/cancer/cga/Firehose">https://software.broadinstitute.org/cancer/cga/Firehose</ext-link>), which managed intermediate analysis files executed by analysis pipelines. Sequencing data were incorporated into quality-control modules in Firehose to compare the tumor and normal genotypes and ensure concordance between samples. Quality-control cutoffs were as follows: mean target coverage &gt;50× (tumor) and &gt;20× (matched normal), cross-contamination of samples estimation (ContEst<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>) &lt;5% and tumor purity ≥10% (Extended Data Fig. <xref rid="MOESM1" ref-type="media">1</xref>).</p>
          <sec id="Sec14">
            <title>Power calculation quality control</title>
            <p id="Par47">To limit our analysis to samples where we had adequate power to call somatic variants, we performed a downstream per-sample power calculation. For each sample, we performed a Monte Carlo simulation of 1,000 true clonal mutations using the following procedures:<list list-type="bullet"><list-item><p id="Par48">Sample the number of reads from the sample-specific coverage distribution</p></list-item><list-item><p id="Par49">Draw the number of tumor reads from a binomial distribution using the estimated tumor purity</p></list-item><list-item><p id="Par50">Draw the number of mutation reads from a binomial distribution given the assumption of a heterozygous mutation and no copy number variation</p></list-item><list-item><p id="Par51">Characterize the mutation as detected or not on the basis of a log odds threshold of 6.3 (consistent with the MuTect<sup><xref ref-type="bibr" rid="CR60">60</xref></sup> implementation).</p></list-item></list></p>
            <p id="Par52">The estimated power to detect clonal mutations is the proportion of simulated mutations detected (for example, 800 detected out of 1,000 simulated clonal mutations is 80% power), which is a function of both sample-specific sequencing depth of coverage and tumor purity. Three tumors were excluded using this threshold (Extended Data Fig. <xref rid="Fig6" ref-type="fig">1</xref>).</p>
          </sec>
          <sec id="Sec15">
            <title>Variant calling</title>
            <p id="Par53">The MuTect algorithm<sup><xref ref-type="bibr" rid="CR60">60</xref></sup> was applied to identify somatic single-nucleotide variants in targeted exons, with computational filtering of artifacts introduced by DNA oxidation during sequencing<sup><xref ref-type="bibr" rid="CR61">61</xref></sup> or FFPE-based DNA extraction using a filter-based method. Strelka<sup><xref ref-type="bibr" rid="CR62">62</xref></sup> was applied to identify small insertions or deletions. Identified alterations were annotated using Oncotator<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>.</p>
          </sec>
          <sec id="Sec16">
            <title>TMB and neoantigen load</title>
            <p id="Par54">For purposes of analysis, the TMB was calculated as the log of the number of nonsynonymous mutations detected from WES. Mutations per Mb was calculated by dividing the total number of nonsynonymous mutations by the number of bases with sufficient coverage in the tumor and normal samples (≥14× and ≥8×, respectively) to call mutations (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://software.broadinstitute.org/cancer/cga/mutect">https://software.broadinstitute.org/cancer/cga/mutect</ext-link>). Neoantigen prediction was performed as previously described<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. Briefly, HLA type was inferred using POLYSOLVER<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>, which uses a Bayesian classifier to determine the genotype of each patient. Neoantigens were predicted for each patient by defining all novel nine and ten amino-acid sequences resulting from mutations and determining whether the predicted binding affinity to the patient’s germline HLA alleles was &lt;500 nM using NetMHCpan (v.2.4)<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>.</p>
          </sec>
          <sec id="Sec17">
            <title>Copy number variants</title>
            <p id="Par55">The total number of copy number alterations for individual tumors was inferred using adaptations of a binary segmentation algorithm<sup><xref ref-type="bibr" rid="CR66">66</xref></sup> (CapSeg) comparing fractional exon coverage for tumor segments to a panel of normal samples, generating exomic segments and segment copy number. Copy number data were inspected visually and manually for focal amplifications and deletions and genes were annotated with Oncotator<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>. For allelic copy number alterations, heterozygous single-nucleotide polymorphisms were identified and integrated into the binary segmentation algorithm (Allelic CapSeg) and allelic segments were further adjusted for tumor purity and ploidy using estimates derived from ABSOLUTE<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. We then called allelic amplifications and deletions, following previously described methodology and criteria<sup><xref ref-type="bibr" rid="CR68">68</xref></sup> integrating segment focality and the purity- and ploidy-corrected allelic copy number.</p>
          </sec>
          <sec id="Sec18">
            <title>Purity and ploidy</title>
            <p id="Par56">Purity and ploidy were estimated using the ABSOLUTE algorithm<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>, which integrates variant allele frequency distributions and copy number variants to estimate absolute tumor purity and ploidy and infer the cancer cell fraction, the proportion of cancer cells in the sample that contain each mutation. Allelic segments following purity and ploidy correction were used to estimate allelic copy number.</p>
          </sec>
          <sec id="Sec19">
            <title>Heterogeneity and aneuploidy</title>
            <p id="Par57">Heterogeneity was estimated as the proportion of mutations in each sample that were inferred to be subclonal. Clonal mutations were defined as having a cancer cell fraction ≥0.8, while other mutations were defined as subclonal; we chose this definition as a simple conservative approach with high specificity.</p>
            <p id="Par58">To estimate aneuploidy, we used the proportion of the genome inferred to have an allelic amplification or deletion, using the allelic segmentation described above.</p>
          </sec>
          <sec id="Sec20">
            <title>Mutational signatures</title>
            <p id="Par59">De novo mutational signatures were generated in this cohort using an adaptation of non-negative matrix factorization<sup><xref ref-type="bibr" rid="CR69">69</xref></sup> via the Brunet update method<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>, as previously described in detail<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>, with the R package SomaticSignatures<sup><xref ref-type="bibr" rid="CR71">71</xref></sup> and non-negative matrix factorization<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. Cosine similarity was used to compare the discovered signatures to the 30 existing discovered and validated signatures in COSMIC<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR73">73</xref></sup>, with a threshold of 0.85, and we also manually visualized and inspected similarities in mutational motifs between our signatures and COSMIC signatures.</p>
          </sec>
          <sec id="Sec21">
            <title>Transcriptomic analysis</title>
            <p id="Par60">Whole-transcriptome sequencing data from FFPE tissues were aligned using STAR<sup><xref ref-type="bibr" rid="CR74">74</xref></sup> and quantified with RSEM<sup><xref ref-type="bibr" rid="CR75">75</xref></sup> to yield gene-level expression in transcripts per million (TPM). For RNA-seq quality control, sequencing- and alignment-specific metrics were considered for each sample. The following alignment metrics (output by the STAR alignment method) were considered: percentage of uniquely mapped reads, average mapped read length, number of splices, mismatch rate per base, percentage of multimapped reads, percentage of reads mapped to too many locations, percentage of unmapped reads due to too many mismatches, percentage of unmapped reads due to reads being too short and percentage of unmapped reads due to other reasons. Additionally, we considered the raw number of reads, the average read length, the read duplication rate and DV200 for each sample. Samples were clustered across quality-control metrics using principal-component analysis, and outlier samples were manually evaluated and discarded. Three samples were removed owing to poor quality: patient 143 was excluded owing to an abnormally low absolute number of reads (number of reads &lt;1 million); patient 107 was excluded owing to an abnormally high percentage of reads mapped to too many locations (&gt;10% of reads), likely indicating high numbers of short or degraded reads; and patient 61 was excluded owing to multiple aberrant quality-control metrics resulting in overall poor quality when considering all metrics in aggregate as well as an aberrant expression profile compared to all other samples. Only transcriptomes from tumors whose WES also passed quality control were included; the final patient cohort for RNA-seq analysis included <italic toggle="yes">n</italic> = 121 transcriptomes.</p>
            <p id="Par61">We excluded certain classes of noncoding genes that constituted a large (&gt;10%) proportion of TPM in the majority of samples. Specifically we excluded genes characterized as snoRNA, using biomaRt<sup><xref ref-type="bibr" rid="CR76">76</xref></sup> to download Ensembl biotype annotations (using the dataset ‘hsapiens_gene_ensembl’ and version ‘GRCh38.p10’) and excluding genes whose biotype was ‘snoRNA’ (<italic toggle="yes">n</italic> = 380 genes). We then regenerated a new TPM metric for each sample to normalize the total transcriptome sum to 1 million.</p>
            <p id="Par62">For analysis, only genes with TPM &gt; 0 in 25% or more of the samples were included. This excluded 6,158 genes, with 20,848 genes passing this threshold.</p>
          </sec>
          <sec id="Sec22">
            <title>GSEA and ssGSEA</title>
            <p id="Par63">GSEA<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> was performed using the Cancer Hallmarks gene sets<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> from MSigDB at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cloud.genepattern.org/">https://cloud.genepattern.org/</ext-link>. We used default settings with 10,000 gene set permutations to generate <italic toggle="yes">P</italic> and <italic toggle="yes">q</italic> values, and we compared progressors and responders in the overall cohort, the ipilimumab-treated subgroup and the ipilimumab-naive subgroup separately.</p>
            <p id="Par64">To generate nonparametric gene set scores in individual samples, we generated ssGSEA projections<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> for gene sets using rank normalization, including the MHC-II HLA genes (<italic toggle="yes">HLA-DMA</italic>, <italic toggle="yes">HLA-DMB</italic>, <italic toggle="yes">HLA-DOA</italic>, <italic toggle="yes">HLA-DOB</italic>, <italic toggle="yes">HLA-DPA1</italic>, <italic toggle="yes">HLA-DPB1</italic>, <italic toggle="yes">HLA-DQA1</italic>, <italic toggle="yes">HLA-DQA2</italic>, <italic toggle="yes">HLA-DQB1</italic>, <italic toggle="yes">HLA-DQB2</italic>, <italic toggle="yes">HLA-DRA</italic>, <italic toggle="yes">HLA-DRB1</italic> and <italic toggle="yes">HLA-DRB5</italic>) and MHC-I HLA genes (<italic toggle="yes">HLA-A</italic>, <italic toggle="yes">HLA-B</italic>, <italic toggle="yes">HLA-C</italic>, <italic toggle="yes">HLA-E</italic>, <italic toggle="yes">HLA-F</italic>, <italic toggle="yes">TAP1</italic>, <italic toggle="yes">TAP2</italic> and <italic toggle="yes">B2M</italic>). ssGSEA scores were also generated for Cancer Hallmarks gene sets.</p>
          </sec>
          <sec id="Sec23">
            <title>Absolute immune infiltrate and immune subsets</title>
            <p id="Par65">Estimation of the total immune infiltrate in each sample and immune cell subsets was performed using CIBERSORT with the LM22 gene set<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> on the CIBERSORT website (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cibersort.stanford.edu">http://cibersort.stanford.edu</ext-link>). The absolute mode was enabled and quantile normalization was disabled using the RNA-seq TPM matrix for the cohort.</p>
            <p id="Par66">A separate immune infiltrate and immune cell subsets score analysis was performed using single-cell-derived signatures, and the methodology used for generating normalized signature scores was as described by Jerby-Arnon and colleagues<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>.</p>
            <p id="Par67">As there is no gold standard for inferring immune infiltrate from bulk RNA-seq data, we chose to use CIBERSORT-inferred values throughout the analysis to allow comparisons with other studies, as CIBERSORT has been widely used (for example, in a pan-TCGA immune landscape analysis<sup><xref ref-type="bibr" rid="CR77">77</xref></sup>).</p>
          </sec>
          <sec id="Sec24">
            <title>Gene expression signatures</title>
            <p id="Par68">Published gene expression signatures related to immune-checkpoint response were collected from the literature and validated in our cohort<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR40">40</xref></sup>. Sample-wise scores for these gene signatures were calculated from RNA-seq data using TPM values and following the methodology described in corresponding studies. Genes with unavailable expression data were excluded from calculations of gene signature scores. In two gene signatures<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>, genes were incorporated independently (that is, weighted) into the published model, but neither the direction nor the coefficient was available, so these signatures were excluded from evaluation. Differences in immune signature scores between responders (CR and PR) and progressors (PD) across all samples, in the ipilimumab-naive subset and in the ipilimumab-treated subset were tested using the Mann–Whitney <italic toggle="yes">U</italic>-test. The predictive utility of these immune signatures was evaluated with AUC values derived from ROC curves of gene signature scores in the complete cohort, ipilimumab-naive subset and the ipilimumab-treated subset. Results and detailed descriptions of evaluated gene signatures are provided in Supplementary Table <xref rid="MOESM4" ref-type="media">6</xref>.</p>
          </sec>
        </sec>
        <sec id="Sec25">
          <title>Analysis</title>
          <p id="Par69">Two primary response comparisons were made: (1) responders (defined as having CR or PR as the best RECIST response) versus progressors (defined as having PD as the best RECIST response) and (2) progressors (defined as having non-PD as the best RECIST response) versus non-progressors.</p>
          <p id="Par70">Statistical tests were performed utilizing the Python <italic toggle="yes">scipy.stats</italic> package. To compare numeric features between response categories, including transcriptome expression, a nonparametric MWW rank-sum test (<italic toggle="yes">mannwhitneyu</italic>() function) was used to minimize the effects of outliers. For comparison of the proportion between response categories, a chi-squared test (<italic toggle="yes">chi2_contingency</italic>() function) was utilized. For association of binary variables (for example, association of gene alteration with responders versus progressors), a Fisher’s exact test (<italic toggle="yes">fisher_exact</italic>() function) was utilized to generate a <italic toggle="yes">P</italic> value. A conservative adjusted OR was generated by repeating the Fisher’s exact test, adding one to both the number of gene-mutant responders and progressors. All tests were two sided unless otherwise indicated.</p>
          <p id="Par71">Survival analyses were performed utilizing the Python <italic toggle="yes">lifelines</italic> package<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>. For Kaplan–Meier curve survival analysis, a log-rank test (<italic toggle="yes">logrank_test()</italic> function) was used to compare survival curves.</p>
          <p id="Par72">Hierarchical clustering was performed using the <italic toggle="yes">clustermap()</italic> function from the Python <italic toggle="yes">seaborn</italic> package<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>, with default settings including a Euclidean distance metric and the ‘single’ method of calculating cluster distance (minimization of the nearest point between clusters).</p>
        </sec>
        <sec id="Sec26">
          <title>Validation</title>
          <p id="Par73">For validation, we reviewed the literature and found three studies<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup> of advanced melanoma treated with anti-PD1 ICB with response, WES and RNA-seq data. However, one did not have information on previous ipilimumab treatment<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, and another<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> had only two patients who were naive to ipilimumab and nine who were treated with ipilimumab with post-ipilimumab tumor biopsies and available WES and NanoString data; thus, we used the remaining cohort<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> as our primary validation cohort.</p>
          <p id="Par74">To allow appropriate validation, only cutaneous, occult, acral and mucosal samples were included from validation cohorts; specifically, uveal and ocular melanomas were excluded (Riaz cohort, <italic toggle="yes">n</italic> = 5 excluded). Only patients with evaluable response criteria were included (Riaz cohort, <italic toggle="yes">n</italic> = 2 excluded). WES, transcriptomic and heterogeneity data were obtained from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/riazn/bms038_analysis">https://github.com/riazn/bms038_analysis</ext-link>. Fragments per kilobase of transcript per million mapped reads values were converted to TPM to be consistent with our cohort normalization.</p>
        </sec>
        <sec id="Sec27">
          <title>Predictive model generation and cross-validation</title>
          <p id="Par75">We used logistic regression for our model to predict PD as the best RECIST response versus non-PD rather than responder versus progressor to better reflect the real-world setting where all outcomes (PD, SD, MR, PR and CR) are possible. We evaluated genomic, transcriptomic and clinical features. Categorical features were converted to binary features for each categorical value. To be conservative, no gene-level mutations or expression values were individually considered. Global genomic tumor characteristics such as TMB, purity, ploidy, heterogeneity and aneuploidy were considered. Features were generated from the transcriptome, including ssGSEA values for gene sets representing Cancer Hallmarks pathways, and MHC-II and MHC-I antigen-presentation genes, as well as gene expression signatures following the methodology in the respective publications, as described above and in Supplementary Table <xref rid="MOESM4" ref-type="media">6</xref>. Clinical characteristics including LDH and ECOG at the start of anti-PD1 ICB, the number of metastatic organs, sex, M stage, the number of different metastatic sites, metastatic sites and melanoma subtype were evaluated (Supplementary Table <xref rid="MOESM4" ref-type="media">1</xref>). Features were chosen in a forward-selection-based process, where features that were significantly predictive (<italic toggle="yes">P</italic> &lt; 0.05) when added to the base model were ranked on the basis of the ability of the combined model to discriminate outcomes (using ROC curve AUC as the metric), and the best feature was chosen to be added to the base model. Potential features were evaluated on the basis of a manual review considering biological interpretability and clinical applicability. This process was iterated with the new base model and stopped when no features under consideration were significantly predictive.</p>
          <p id="Par76">The set of tumors with both WES and RNA-seq data was smaller than the set of tumors with only WES data; when the features chosen in model development for ipilimumab-naive tumors resulted in only WES features being chosen, model development was repeated in the superset of tumors requiring only clinical and WES data, and this model in the larger set is reported in the main text.</p>
          <p id="Par77">To estimate the ‘out-of-bag’ AUC, we used <italic toggle="yes">k</italic>-fold cross-validation (splitting the dataset into <italic toggle="yes">k-</italic>subsets, training on <italic toggle="yes">k</italic> − 1 subsets and calculating AUC on the holdout subset) and calculated the mean cross-validation AUC. Given the partially manual review of features, feature selection was not included in cross-validation. For the ipilimumab-treated subset (<italic toggle="yes">n</italic> = 34), we chose <italic toggle="yes">k</italic> = 5 folds, and for the larger ipilimumab-naive subset (<italic toggle="yes">n</italic> = 85), we chose <italic toggle="yes">k</italic> = 10 folds, to maintain a cross-validation holdout set of &gt;5 tumors. Cross-validation scores were calculated using the <italic toggle="yes">cross_val_score</italic> function from the Python <italic toggle="yes">sklearn</italic> package.</p>
          <p id="Par78">To further evaluate the statistical support for our models, we calculated the Akaike information criteria and BIC of each subsequent model after adding an additional feature in forward selection in the ipilimumab-experienced and ipilimumab-naive subgroups (Extended Data Fig. <xref rid="Fig13" ref-type="fig">8c,d</xref>), and we also evaluated the addition of TMB as an additional feature to the selected models.</p>
        </sec>
        <sec id="Sec28">
          <title>Permutation testing</title>
          <p id="Par79">To test the statistical significance of differences in FDR <italic toggle="yes">q</italic> values of enriched pathways between ipilimumab-naive versus ipilimumab-experienced subgroups, we performed a permutation analysis. Briefly, we shuffled the ipilimumab-experienced and ipilimumab-naive labels for each tumor, keeping each subgroup size the same and keeping the same number of responders and progressors in each subgroup, and we reran GSEA on each new simulated subgroup. We repeated this 1,000 times to generate a distribution of enriched pathways in each subgroup under the null hypothesis of no relationship between subgroup and pathway enrichment. We then compared our observed outcome within this null distribution to generate an empiric <italic toggle="yes">P</italic> value. For example, for each pathway enriched in ipilimumab-experienced patients, the proportion of simulations with a difference in log <italic toggle="yes">q</italic> value between ipilimumab-experienced and ipilimumab-naive subgroups (equivalent to the ratio of <italic toggle="yes">q</italic> values) greater than or equal to our observed difference, and with an FDR <italic toggle="yes">q</italic> value in the ipilimumab-experienced subgroup equal to or more extreme than our observed ipilimumab-experienced <italic toggle="yes">q</italic> value would represent the empiric <italic toggle="yes">P</italic> value.</p>
          <p id="Par80">We performed a similar permutation test to generate an empiric <italic toggle="yes">P</italic> value for the predictive models for ipilimumab-experienced and ipilimumab-naive subgroups. Briefly, we permuted the outcome labels (progressors and non-progressors) within each subgroup, and generated an AUC and cross-validation AUC for the predictive model with the specified features (that is, MHC-II, LDH and lymph node metastasis for ipilimumab-experienced tumors; purity, ploidy and heterogeneity for ipilimumab-naive tumors) to generate a null distribution of AUCs and cross-validation AUCs under the null hypothesis that these predictors are not associated with outcomes. By permuting the phenotype rather than the predictors, we preserved the inter-predictor structure. Then, the proportion of simulations with AUC and cross-validation AUC greater than our observed AUC represented an empiric <italic toggle="yes">P</italic> value.</p>
        </sec>
        <sec id="Sec29">
          <title>Reporting Summary</title>
          <p id="Par81">Further information on research design is available in the <xref rid="MOESM1" ref-type="media">Nature Research Reporting Summary</xref> linked to this article.</p>
        </sec>
      </sec>
      <sec id="Sec30" sec-type="materials|methods">
        <title>Online content</title>
        <p id="Par82">Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41591-019-0654-5.</p>
      </sec>
      <sec sec-type="supplementary-material">
        <title>Supplementary information</title>
        <p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41591_2019_654_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41591_2019_654_MOESM2_ESM.xlsx" position="float" orientation="portrait"><label>Supplementary Data 1</label><caption><p>Gene-level mutation calls; copy number alterations; immune cell signatures; mutational signatures; and ssGSEA signatures using Hallmarks gene sets.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41591_2019_654_MOESM3_ESM.txt" position="float" orientation="portrait"><label>Supplementary Data 2</label><caption><p>RNA-seq TPM matrix.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41591_2019_654_MOESM4_ESM.xlsx" position="float" orientation="portrait"><label>Supplementary Tables</label><caption><p>Supplementary Tables 1–9.</p></caption></media></supplementary-material>
</p>
      </sec>
    </body>
    <back>
      <app-group>
        <app id="App1">
          <sec id="Sec31">
            <title>Extended data</title>
            <p id="Par86">
<fig id="Fig6" position="float" orientation="portrait"><label>Extended Data Fig. 1</label><caption><p>Consort Diagram showing inclusion, exclusion, and quality control criteria for patients/tumors included in analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d30e3508" orientation="portrait" xlink:href="41591_2019_654_Fig6_ESM.jpg"/></fig>
</p>
            <p id="Par87">
<fig id="Fig7" position="float" orientation="portrait"><label>Extended Data Fig. 2</label><caption><title>Survival and genomic copy number characteristics of responders (n = 55 patients) (defined as CR or PR as best response) vs. progressors (n = 65 patients) (defined as PD as best response).</title><p>(a) PFS Kaplan Meier survival curves; two-sided log-rank p = 2.1e-28 (b) OS Kaplan Meier survival curves; two-sided log-rank p = 5.1e-18 (c) Proportion of tumor genome with copy number alterations (two-sided MWW p = 0.09). Boxplots: Box limits indicate the interquartile range (25th-75th percentile), with a center line indicating the median. Whiskers show the value ranges up to 1.5xIQR above the 75th or below the 25th percentile, with outliers beyond those ranges shown as individual points. PD = progressive disease. CR = complete response. PR = partial response.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d30e3522" orientation="portrait" xlink:href="41591_2019_654_Fig7_ESM.jpg"/></fig>
</p>
            <p id="Par88">
<fig id="Fig8" position="float" orientation="portrait"><label>Extended Data Fig. 3</label><caption><title>Association of Genomic Alterations in Genes with Response vs. Progression.</title><p>For each gene, the association of a genomic alteration with response was tested using a two-sided Fisher’s Exact test, and the odds ratio (OR) and p-value calculated. The adjusted OR is a conservative estimate generated by adding 1 to both mutant gene responders and progressors, thus moving the OR estimate closer to 1. The x- and y-axis are on log scales, but labeled in the original units. (<bold>a</bold>) Association of gene mutations with response (n = 55 patients) vs. progression (n = 65 patients). (<bold>b</bold>) Association of gene amplifications with response (n = 55 patients) vs. progression (n = 65 patients).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d30e3542" orientation="portrait" xlink:href="41591_2019_654_Fig8_ESM.jpg"/></fig>
</p>
            <p id="Par89">
<fig id="Fig9" position="float" orientation="portrait"><label>Extended Data Fig. 4</label><caption><title>Amplification of Chromosome 6 Regions in TAP2, HLA-A/B/C amplified tumors.</title><p>Patients with amplifications in TAP2 or HLA-A/B/C are shown, with inferred amplifications in the relevant section of Chromosome 6 shown. 6 patients had amplifications in TAP2, 6 patients had amplifications in HLA-A/B/C, and 4 patients had amplifications of a chromosomal region including all four genes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d30e3556" orientation="portrait" xlink:href="41591_2019_654_Fig9_ESM.jpg"/></fig>
</p>
            <p id="Par90">
<fig id="Fig10" position="float" orientation="portrait"><label>Extended Data Fig. 5</label><caption><title>Hierarchical clustering of the correlation matrix between transcriptional signatures previously associated with immunotherapy response and hallmark gene-sets, genomic, clinical, and transcriptomic features associated with response in our cohort.</title><p>The color indicates the Pearson correlation between features, from perfect negative correlation (Pearson r = -1, blue) to perfect positive correlation (Pearson r = 1, red). Most previously hypothesized signatures cluster within an immune-activity related group with immune-related gene-sets. Sample size for each correlation depends on the number of available data points: correlations involving exclusively genomic or clinical data had n = 144 tumor samples, while correlations involving transcriptomic features had n = 121 tumor samples with data available.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d30e3570" orientation="portrait" xlink:href="41591_2019_654_Fig10_ESM.jpg"/></fig>
</p>
            <p id="Par91">
<fig id="Fig11" position="float" orientation="portrait"><label>Extended Data Fig. 6</label><caption><title>Expression of Genomic Features in Responders vs. Progressors in ipilimumab-treated and -naive subsets.</title><p>Two-sided Mann-Whitney-Wilcoxon tests were used to compare responders to progressors (ipilimumab-treated: n = 16 responders/20 progressors; ipilimumab-naïve: n = 34 responders/37 progressors). All p-values are unadjusted. Log Nonsyn Mutload: Ipi-treated p = 0.15; Ipi-naïve p = 0.15. Log Clonal Mutload: Ipi-treated p = 0.17; Ipi-naïve p = 0.08. Heterogeneity: Ipi-treated p = 0.51; Ipi-naïve p = 0.057. Ploidy: Ipi-treated p = 0.45; Ipi-naïve p = 0.002. Boxplots: Box limits indicate the interquartile range (25th-75th percentile), with a center line indicating the median. Whiskers show the value ranges up to 1.5xIQR above the 75th or below the 25th percentile, with outliers beyond those ranges shown as individual points.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d30e3584" orientation="portrait" xlink:href="41591_2019_654_Fig11_ESM.jpg"/></fig>
</p>
            <p id="Par92">
<fig id="Fig12" position="float" orientation="portrait"><label>Extended Data Fig. 7</label><caption><title>Survival of patients stratified by progressive disease (PD) or non-PD (SD, MR, PR, or CR) best response (RECIST 1.1) to PD-1 ICB.</title><p>(<bold>a</bold>) PFS (two-sided logrank p = 4.0e-38 (<bold>b</bold>) OS (two-sided logrank p = 1.2e-19).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d30e3604" orientation="portrait" xlink:href="41591_2019_654_Fig12_ESM.jpg"/></fig>
</p>
            <p id="Par93">
<fig id="Fig13" position="float" orientation="portrait"><label>Extended Data Fig. 8</label><caption><title>Model selection criteria with increasing number of features by forward selection; cross-validation AUC distribution of final models.</title><p>(<bold>a</bold>) Model AUC for the ipi-treated subgroup. Each point is labeled with the additional feature, and the final model includes MHC-II, Lymph node metastasis, and LDH below the median as features. (<bold>b</bold>) Model AUC for the ipi-naive subgroup. Each point is labeled with the additional feature, and the final model includes ploidy, heterogeneity, and purity as features. (<bold>c</bold>) Model AIC/BIC for the ipi-experienced subgroup. (<bold>d</bold>) Model AIC/BIC for the ipi-naïve subgroup. (<bold>e</bold>) Using 10-fold crossvalidation in the ipilimumab-naïve subset, mean crossvalidation AUC is 0.73, with a SD of 0.25. Each fold split the cohort into a training (n = 74 patients) and test set (n = 10 patients) ((<bold>f</bold>) In the ipi-experienced subset, mean crossvalidation AUC is 0.85, with a SD of 0.18. Each fold split the cohort into a training (n = 27 patients) and test set (n = 7 patients).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d30e3637" orientation="portrait" xlink:href="41591_2019_654_Fig13_ESM.jpg"/></fig>
</p>
            <p id="Par94">
<fig id="Fig14" position="float" orientation="portrait"><label>Extended Data Fig. 9</label><caption><title>Subgroup Model ROC curves applied to other subgroups.</title><p>(<bold>a</bold>) Ipilimumab-treated subgroup model applied to ipilimumab-naive (n = 74 patients) subgroup; (<bold>b</bold>) Ipilimumab-naive model applied to ipilimumab-treated (n = 45 patients) subgroup; (<bold>c</bold>) Ipi-naïve model predicting PD as best response to PD-1 ICB applied to pre-ipilimumab-treated (n = 15 patients) tumors. (top) Comut plot overlaying best response and the ipi-naïve model score. Each column is one of 15 ipilimumab-treated tumors biopsied prior to ipilimumab therapy, ordered by the predictive model score. The 5 highest scoring tumors were all PD. (bottom) Receiver-operator curve for our ipilimumab-naive predictive model applied to pre-ipilimumab tumors (n = 15), with an AUC of 0.71.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d30e3660" orientation="portrait" xlink:href="41591_2019_654_Fig14_ESM.jpg"/></fig>
</p>
            <p id="Par95">
<fig id="Fig15" position="float" orientation="portrait"><label>Extended Data Fig. 10</label><caption><title>Limited validation testing single feature models in validation cohort.</title><p>(<bold>a</bold>) Relationship between response and MHC-II HLA score in the ipilimumab-treated subgroup of a validation cohort. Each column is a patient, and patients are sorted by MHC-II HLA score. (<bold>b</bold>) Validation of Predictive Model for ipilimumab-treated tumors. In a validation cohort (n = 23), a model using the only common available feature (MHC-II HLA score) had an AUC of 0.65 (log likelihood ratio p = 0.09, empiric p = 0.21, <xref rid="Sec9" ref-type="sec">Methods</xref>). (<bold>c</bold>) Relationship between response and MHC-II HLA score in the ipilimumab-treated subgroup of a validation cohort. Each column is a patient, and patients are sorted by MHC-II HLA score. (<bold>d</bold>) Validation of Predictive Model for ipilimumab-naive Tumors. In a validation cohort (n = 20), a model using the only common available feature (heterogeneity) had an AUC of 0.73 (log likelihood ratio p = 0.17, empiric p = 0.066, <xref rid="Sec9" ref-type="sec">Methods</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d30e3693" orientation="portrait" xlink:href="41591_2019_654_Fig15_ESM.jpg"/></fig>
</p>
          </sec>
        </app>
      </app-group>
      <fn-group>
        <fn>
          <p><bold>Peer review information</bold> Saheli Sadanand was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.</p>
        </fn>
        <fn>
          <p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
        </fn>
        <fn>
          <p>These authors contributed equally: David Liu, Bastian Schilling.</p>
        </fn>
        <fn>
          <p>
            <bold>Change history</bold>
          </p>
          <p>6/19/2020</p>
          <p>An amendment to this paper has been published and can be accessed via a link at the top of the paper.</p>
        </fn>
      </fn-group>
      <sec>
        <sec id="FPar1">
          <title>Extended data</title>
          <p id="Par83">is available for this paper at 10.1038/s41591-019-0654-5.</p>
        </sec>
        <sec id="FPar2" sec-type="supplementary-material">
          <title>Supplementary information</title>
          <p id="Par84">is available for this paper at 10.1038/s41591-019-0654-5.</p>
        </sec>
      </sec>
      <ack>
        <title>Acknowledgements</title>
        <p>The authors thank the active investigators A. Gesierich (University Hospital Würzburg), J.C. Hassel (NCT Heidelberg), C. Pföhler (Saarland University Medical Center), E. Dabrowski (Ludwigshafen Medical Center), L.A. Schneider (University Medical Center Ulm), C. Weishaupt (University Hospital of Münster), K.G. Griewank (University Hospital Essen), E. Hadaschik (University Hospital Essen), G. Kyriakakis (Laikon General Hospital), F. Meier (NCT Dresden), M.H. Geukes Foppen (The Netherlands Cancer Institute), R. Dummer (University Hospital Zürich), E. Bräunlein (Technical University Munich) and M. Boxberg (Technical University Munich) for providing additional patient samples and clinical data. The authors also thank A. Giobbie-Hurder (Dana-Farber Cancer Institute) and J. Weirather (Dana-Farber Cancer Institute) for useful discussions regarding statistical testing. This work was supported by the Adelson Medical Research Foundation (L.G.), the Conquer Cancer Foundation (David Liu), the Society for Immunotherapy of Cancers (David Liu), the Damon Runyon Cancer Research Foundation (David Liu), the BroadNext10 (E.M.V.), the National Institutes of Health (K08 CA234458 (David Liu), R01 CA227388 (E.M.V.), U01 CA233100 (E.M.V.), T32 GM008313 (M.X.H.)), the Deutsche Forschungsgemeinschaft (German Research Foundation), SCHA 422/17-1, PA 2376/1-1 and HO 6389/2-1 (KFO 337; D.S, A.P.) and National Science Foundation Graduate Research Fellowship Program DGE1144152 (M.X.H.).</p>
      </ack>
      <notes notes-type="author-contribution">
        <title>Author contributions</title>
        <p>David Liu, B.S., L.G., A.R., K.F., E.M.V.A. and D.S. conceived and designed the overall study. B.S. collected and reviewed all clinical data. A.S. performed sample processing and shipping. B.S., E.L., L.Z., R.G., I.S., C.L., S.G., H.G., S.M.G., J.U., C.U.B, R.R., D.v.B., A.K., B.W., S.H. and F.K. provided samples and clinical annotation. A.T. oversaw sample processing and sequencing. David Liu, C.A.M., N.V., J.C., D.M., F.D. and M.X.H. designed and performed the mutational and copy number analyses. David Liu, Derek Liu, C.A.M., M.X.H., D.M., L.J.-A. and B.I. designed and performed RNA-seq analysis, including quality control, normalization, signature analysis, CIBERSORT and GSEA. David Liu, H.E. and M.X.H. designed and constructed the predictive modeling. David Liu, B.S., A.P., E.M.V.A. and D.S. interpreted the data. David Liu, B.S., E.M.V.A. and D.S. wrote the manuscript, and all authors reviewed and approved the final manuscript.</p>
      </notes>
      <notes notes-type="data-availability">
        <title>Data availability</title>
        <p>All reasonable requests for raw and analyzed data and materials will be promptly reviewed by the senior authors to determine whether the request is subject to any intellectual property or confidentiality obligations. Patient-related data not included in the paper may be subject to patient confidentiality. Any data and materials that can be shared will be released via a material transfer agreement. All analyzed sequencing data are in supplementary tables or data available online. Raw sequencing data are available in dbGaP (accession number <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000452.v3.p1">phs000452.v3.p1</ext-link>).</p>
      </notes>
      <notes notes-type="data-availability">
        <title>Code availability</title>
        <p>Python code is available in packages as described in the manuscript. Code to regenerate figures using supplementary data and tables is available at GitHub at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/vanallenlab/schadendorf-pd1">https://github.com/vanallenlab/schadendorf-pd1</ext-link>. Additional reasonable requests for code will be promptly reviewed by the senior authors to verify whether the request is subject to any intellectual property or confidentiality obligations, and shared to the extent permissible by these obligations.</p>
      </notes>
      <notes id="FPar3" notes-type="COI-statement">
        <title>Competing interests</title>
        <p id="Par85">David Liu reports funding by a postdoctoral fellowship from the Society for Immunotherapy of Cancers, which is funded in part by an educational grant from Bristol-Meyers Squibb (BMS). BMS has had no input into the conception, conduct or reporting of the submitted work. B.S. is on the advisory board or has received honoraria from Incyte, Novartis, Roche, BMS and Merck Sharp &amp; Dohme (MSD), research funding from Pierre-Fabre Pharmaceuticals, BMS and MSD and travel support from Novartis, Roche, BMS, Pierre-Fabre Pharmaceuticals, MSD and Amgen, outside the scope of the submitted work. D.S. reports grants, personal fees and nonfinancial support from BMS, personal fees and nonfinancial support from Roche, grants, personal fees and nonfinancial support from Novartis, nonfinancial support from Regeneron, personal fees from Sanofi, personal fees and nonfinancial support from MSD, personal fees and nonfinancial support from Amgen, personal fees and nonfinancial support from 4SC, personal fees and nonfinancial support from Merck-EMD, personal fees from Array, personal fees and nonfinancial support from Pierre-Fabre, personal fees and nonfinancial support from Philogen, personal fees and nonfinancial support from Incyte and personal fees from Pfizer, outside the scope of the submitted work. E.M.V.A. reports advisory relationships and consulting with Tango Therapeutics, Genome Medical, Invitae, Illumina and Ervaxx; research support from Novartis and BMS; equity in Tango Therapeutics, Genome Medical, Syapse, Ervaxx and Microsoft; and travel reimbursement from Roche and Genentech, outside the submitted work. S.G. reports personal fees from MSD, personal fees from BMS, personal fees from Novartis and personal fees from Roche, outside the scope of the submitted work. L.Z. reports personal fees and others from BMS, personal fees and others from Novartis, personal fees and others from Pierre-Fabre, personal fees and others from MSD, personal fees from Roche, other fees from Amgen and personal fees from Sanofi, outside the scope of the submitted work. F.K. reports personal fees from Amgen, personal fees from BMS, grants and personal fees from Novartis, personal fees from Roche, personal fees from MSD and personal fees from Merck, outside the submitted work. J.U. reports personal fees and nonfinancial support from Amgen, personal fees and nonfinancial support from BMS, personal fees and nonfinancial support from MSD, personal fees and nonfinancial support from Novartis, personal fees and nonfinancial support from Pierre-Fabre, and personal fees and nonfinancial support from Roche, outside the scope of the submitted work. H.G. reports grants and personal fees from BMS, grants and personal fees from Roche, grants and personal fees from MSD, grants and personal fees from Novartis, personal fees from Amgen and personal fees from Pierre-Fabre, outside the scope of the submitted work. R.G. reports personal fees and nonfinancial support from BMS, personal fees and nonfinancial support from Roche Pharma, personal fees and nonfinancial support from Merck Serono, grants, personal fees and nonfinancial support from Amgen, personal fees and nonfinancial support from Pierre-Fabre, personal fees and nonfinancial support from Sanofi Regeneron, personal fees from MSD, grants, personal fees and nonfinancial support from Novartis, personal fees and nonfinancial support from Almirall Hermal, grants and personal fees from Pfizer, personal fees from LEO, personal fees from AstraZeneca, personal fees from Sun Pharma, personal fees from 4SC and grants from Johnson &amp; Johnson, outside the scope of the submitted work. I.S. reports grants and personal fees from Novartis, grants from Pfizer, personal fees from Roche, personal fees BMS and personal fees from MSD, outside the scope of the submitted work. C.L. reports personal fees from Roche, personal fees from Novartis, personal fees from Pierre-Fabre, personal fees from BMS, personal fees from MSD, personal fees from Amgen and personal fees from Idera and Sun Pharma, outside the scope of the submitted work. S.G. reports personal fees from BMS, personal fees from MSD and personal fees from Merck KGaA, outside the scope of the submitted work. E.L. reports personal fees and others from Amgen, personal fees and others from BMS, personal fees and others from MSD, personal fees and others from Novartis, personal fees and others from Roche, personal fees from medac, personal fees from Janssen, other fees from Actelion and other fees from Pierre-Fabre, outside the scope of the submitted work. A.K. reports grants from BMS and Kiadis, personal fees from BMS, Sanofi, Novartis, Roche, Vaccibody and nonfinancial support from Sanofi and BMS, outside the scope of the submitted work. C.B. reports personal fees from BMS, MSD, Roche, Novartis, GSK, Pfizer, Lilly, Pierre-Fabre and GenMab and grants from BMS, Novartis and NanoString, outside the scope of the submitted work. S.H. reports personal fees from Novartis, personal fees from BMS, personal fees from Amgen, personal fees from Pierre-Fabre and personal fees from Roche, outside the scope of the submitted work. B.W. reports grants and personal fees from Philogen, personal fees from Curevac, grants and personal fees from MSD, grants and personal fees from BMS and personal fees from GSK, outside the scope of the submitted work. R.R. reports personal fees from Novartis, personal fees and nonfinancial support from Amgen and nonfinancial support from BMS, outside the scope of the submitted work. D.v.B., A.S. and A.P. have nothing to disclose.</p>
      </notes>
      <ref-list id="Bib1">
        <title>References</title>
        <ref id="CR1">
          <label>1.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hodi</surname>
                <given-names>FS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Improved survival with ipilimumab in patients with metastatic melanoma</article-title>
            <source>N. Engl. J. Med.</source>
            <year>2010</year>
            <volume>363</volume>
            <fpage>711</fpage>
            <lpage>723</lpage>
            <pub-id pub-id-type="pmid">20525992</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1003466</pub-id>
            <pub-id pub-id-type="pmcid">PMC3549297</pub-id>
          </element-citation>
        </ref>
        <ref id="CR2">
          <label>2.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Pembrolizumab versus ipilimumab in advanced melanoma</article-title>
            <source>N. Engl. J. Med.</source>
            <year>2015</year>
            <volume>372</volume>
            <fpage>2521</fpage>
            <lpage>2532</lpage>
            <pub-id pub-id-type="pmid">25891173</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1503093</pub-id>
          </element-citation>
        </ref>
        <ref id="CR3">
          <label>3.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wolchok</surname>
                <given-names>JD</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Overall survival with combined nivolumab and ipilimumab in advanced melanoma</article-title>
            <source>N. Engl. J. Med.</source>
            <year>2017</year>
            <volume>377</volume>
            <fpage>1345</fpage>
            <lpage>1356</lpage>
            <pub-id pub-id-type="pmid">28889792</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1709684</pub-id>
            <pub-id pub-id-type="pmcid">PMC5706778</pub-id>
          </element-citation>
        </ref>
        <ref id="CR4">
          <label>4.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Reck</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer</article-title>
            <source>N. Engl. J. Med.</source>
            <year>2016</year>
            <volume>375</volume>
            <fpage>1823</fpage>
            <lpage>1833</lpage>
            <pub-id pub-id-type="pmid">27718847</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1606774</pub-id>
          </element-citation>
        </ref>
        <ref id="CR5">
          <label>5.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Rosenberg</surname>
                <given-names>JE</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <volume>387</volume>
            <fpage>1909</fpage>
            <lpage>1920</lpage>
            <pub-id pub-id-type="pmid">26952546</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(16)00561-4</pub-id>
            <pub-id pub-id-type="pmcid">PMC5480242</pub-id>
          </element-citation>
        </ref>
        <ref id="CR6">
          <label>6.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Motzer</surname>
                <given-names>RJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Nivolumab versus everolimus in advanced renal-cell carcinoma</article-title>
            <source>N. Engl. J. Med.</source>
            <year>2015</year>
            <volume>373</volume>
            <fpage>1803</fpage>
            <lpage>1813</lpage>
            <pub-id pub-id-type="pmid">26406148</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1510665</pub-id>
            <pub-id pub-id-type="pmcid">PMC5719487</pub-id>
          </element-citation>
        </ref>
        <ref id="CR7">
          <label>7.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Seiwert</surname>
                <given-names>TY</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial</article-title>
            <source>Lancet Oncol.</source>
            <year>2016</year>
            <volume>17</volume>
            <fpage>956</fpage>
            <lpage>965</lpage>
            <pub-id pub-id-type="pmid">27247226</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(16)30066-3</pub-id>
          </element-citation>
        </ref>
        <ref id="CR8">
          <label>8.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Rizvi</surname>
                <given-names>NA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer</article-title>
            <source>Science</source>
            <year>2015</year>
            <volume>348</volume>
            <fpage>124</fpage>
            <pub-id pub-id-type="pmid">25765070</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaa1348</pub-id>
            <pub-id pub-id-type="pmcid">PMC4993154</pub-id>
          </element-citation>
        </ref>
        <ref id="CR9">
          <label>9.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Snyder</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genetic basis for clinical response to CTLA-4 blockade in melanoma</article-title>
            <source>N. Engl. J. Med.</source>
            <year>2014</year>
            <volume>371</volume>
            <fpage>2189</fpage>
            <lpage>2199</lpage>
            <pub-id pub-id-type="pmid">25409260</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1406498</pub-id>
            <pub-id pub-id-type="pmcid">PMC4315319</pub-id>
          </element-citation>
        </ref>
        <ref id="CR10">
          <label>10.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Van Allen</surname>
                <given-names>EM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genomic correlates of response to CTLA-4 blockade in metastatic melanoma</article-title>
            <source>Science</source>
            <year>2015</year>
            <volume>350</volume>
            <fpage>207</fpage>
            <lpage>211</lpage>
            <pub-id pub-id-type="pmid">26359337</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aad0095</pub-id>
            <pub-id pub-id-type="pmcid">PMC5054517</pub-id>
          </element-citation>
        </ref>
        <ref id="CR11">
          <label>11.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cristescu</surname>
                <given-names>R</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy</article-title>
            <source>Science</source>
            <year>2018</year>
            <volume>362</volume>
            <fpage>eaar3593</fpage>
            <pub-id pub-id-type="pmid">30309915</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aar3593</pub-id>
            <pub-id pub-id-type="pmcid">PMC6718162</pub-id>
          </element-citation>
        </ref>
        <ref id="CR12">
          <label>12.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Tumeh</surname>
                <given-names>PC</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>PD-1 blockade induces responses by inhibiting adaptive immune resistance</article-title>
            <source>Nature</source>
            <year>2014</year>
            <volume>515</volume>
            <fpage>568</fpage>
            <lpage>571</lpage>
            <pub-id pub-id-type="pmid">25428505</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature13954</pub-id>
            <pub-id pub-id-type="pmcid">PMC4246418</pub-id>
          </element-citation>
        </ref>
        <ref id="CR13">
          <label>13.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zaretsky</surname>
                <given-names>JM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutations associated with acquired resistance to PD-1 blockade in melanoma</article-title>
            <source>N. Engl. J. Med.</source>
            <year>2016</year>
            <volume>375</volume>
            <fpage>819</fpage>
            <lpage>829</lpage>
            <pub-id pub-id-type="pmid">27433843</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1604958</pub-id>
            <pub-id pub-id-type="pmcid">PMC5007206</pub-id>
          </element-citation>
        </ref>
        <ref id="CR14">
          <label>14.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Sade-Feldman</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Resistance to checkpoint blockade therapy through inactivation of antigen presentation</article-title>
            <source>Nat. Commun.</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>1136</fpage>
            <pub-id pub-id-type="pmid">29070816</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-017-01062-w</pub-id>
            <pub-id pub-id-type="pmcid">PMC5656607</pub-id>
          </element-citation>
        </ref>
        <ref id="CR15">
          <label>15.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy</article-title>
            <source>Cell</source>
            <year>2016</year>
            <volume>167</volume>
            <fpage>397</fpage>
            <lpage>404</lpage>
            <pub-id pub-id-type="pmid">27667683</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2016.08.069</pub-id>
            <pub-id pub-id-type="pmcid">PMC5088716</pub-id>
          </element-citation>
        </ref>
        <ref id="CR16">
          <label>16.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Peng</surname>
                <given-names>W</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Loss of PTEN promotes resistance to T cell-mediated immunotherapy</article-title>
            <source>Cancer Discov.</source>
            <year>2016</year>
            <volume>6</volume>
            <fpage>202</fpage>
            <lpage>216</lpage>
            <pub-id pub-id-type="pmid">26645196</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-15-0283</pub-id>
            <pub-id pub-id-type="pmcid">PMC4744499</pub-id>
          </element-citation>
        </ref>
        <ref id="CR17">
          <label>17.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>George</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma</article-title>
            <source>Immunity</source>
            <year>2017</year>
            <volume>46</volume>
            <fpage>197</fpage>
            <lpage>204</lpage>
            <pub-id pub-id-type="pmid">28228279</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2017.02.001</pub-id>
            <pub-id pub-id-type="pmcid">PMC5408320</pub-id>
          </element-citation>
        </ref>
        <ref id="CR18">
          <label>18.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Roh</surname>
                <given-names>W</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance</article-title>
            <source>Sci. Transl. Med.</source>
            <year>2017</year>
            <volume>9</volume>
            <fpage>eaah3560</fpage>
            <pub-id pub-id-type="pmid">28251903</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aah3560</pub-id>
            <pub-id pub-id-type="pmcid">PMC5819607</pub-id>
          </element-citation>
        </ref>
        <ref id="CR19">
          <label>19.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Davoli</surname>
                <given-names>T</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy</article-title>
            <source>Science</source>
            <year>2017</year>
            <volume>355</volume>
            <fpage>eaaf8399</fpage>
            <pub-id pub-id-type="pmid">28104840</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaf8399</pub-id>
            <pub-id pub-id-type="pmcid">PMC5592794</pub-id>
          </element-citation>
        </ref>
        <ref id="CR20">
          <label>20.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hugo</surname>
                <given-names>W</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma</article-title>
            <source>Cell</source>
            <year>2016</year>
            <volume>165</volume>
            <fpage>35</fpage>
            <lpage>44</lpage>
            <pub-id pub-id-type="pmid">26997480</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2016.02.065</pub-id>
            <pub-id pub-id-type="pmcid">PMC4808437</pub-id>
          </element-citation>
        </ref>
        <ref id="CR21">
          <label>21.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Rooney</surname>
                <given-names>MS</given-names>
              </name>
              <name name-style="western">
                <surname>Shukla</surname>
                <given-names>SA</given-names>
              </name>
              <name name-style="western">
                <surname>Wu</surname>
                <given-names>CJ</given-names>
              </name>
              <name name-style="western">
                <surname>Getz</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Hacohen</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Molecular and genetic properties of tumors associated with local immune cytolytic activity</article-title>
            <source>Cell</source>
            <year>2015</year>
            <volume>160</volume>
            <fpage>48</fpage>
            <lpage>61</lpage>
            <pub-id pub-id-type="pmid">25594174</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2014.12.033</pub-id>
            <pub-id pub-id-type="pmcid">PMC4856474</pub-id>
          </element-citation>
        </ref>
        <ref id="CR22">
          <label>22.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Weber</surname>
                <given-names>JS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial</article-title>
            <source>Lancet Oncol.</source>
            <year>2016</year>
            <volume>17</volume>
            <fpage>943</fpage>
            <lpage>955</lpage>
            <pub-id pub-id-type="pmid">27269740</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(16)30126-7</pub-id>
            <pub-id pub-id-type="pmcid">PMC5474305</pub-id>
          </element-citation>
        </ref>
        <ref id="CR23">
          <label>23.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Van Allen</surname>
                <given-names>EM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine</article-title>
            <source>Nat. Med.</source>
            <year>2014</year>
            <volume>20</volume>
            <fpage>682</fpage>
            <lpage>688</lpage>
            <pub-id pub-id-type="pmid">24836576</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.3559</pub-id>
            <pub-id pub-id-type="pmcid">PMC4048335</pub-id>
          </element-citation>
        </ref>
        <ref id="CR24">
          <label>24.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Birkeland</surname>
                <given-names>E</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Patterns of genomic evolution in advanced melanoma</article-title>
            <source>Nat. Commun.</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>2665</fpage>
            <pub-id pub-id-type="pmid">29991680</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-018-05063-1</pub-id>
            <pub-id pub-id-type="pmcid">PMC6039447</pub-id>
          </element-citation>
        </ref>
        <ref id="CR25">
          <label>25.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Alexandrov</surname>
                <given-names>LB</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Signatures of mutational processes in human cancer</article-title>
            <source>Nature</source>
            <year>2013</year>
            <volume>500</volume>
            <fpage>415</fpage>
            <lpage>421</lpage>
            <pub-id pub-id-type="pmid">23945592</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12477</pub-id>
            <pub-id pub-id-type="pmcid">PMC3776390</pub-id>
          </element-citation>
        </ref>
        <ref id="CR26">
          <label>26.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hayward</surname>
                <given-names>NK</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Whole-genome landscapes of major melanoma subtypes</article-title>
            <source>Nature</source>
            <year>2017</year>
            <volume>545</volume>
            <fpage>175</fpage>
            <lpage>180</lpage>
            <pub-id pub-id-type="pmid">28467829</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature22071</pub-id>
          </element-citation>
        </ref>
        <ref id="CR27">
          <label>27.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Miao</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors</article-title>
            <source>Nat. Genet.</source>
            <year>2018</year>
            <volume>50</volume>
            <fpage>1271</fpage>
            <lpage>1281</lpage>
            <pub-id pub-id-type="pmid">30150660</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0200-2</pub-id>
            <pub-id pub-id-type="pmcid">PMC6119118</pub-id>
          </element-citation>
        </ref>
        <ref id="CR28">
          <label>28.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>McGranahan</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Allele-specific HLA loss and immune escape in lung cancer evolution</article-title>
            <source>Cell</source>
            <year>2017</year>
            <volume>171</volume>
            <fpage>1259</fpage>
            <lpage>1271</lpage>
            <pub-id pub-id-type="pmid">29107330</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2017.10.001</pub-id>
            <pub-id pub-id-type="pmcid">PMC5720478</pub-id>
          </element-citation>
        </ref>
        <ref id="CR29">
          <label>29.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Riaz</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Recurrent SERPINB3 and SERPINB4 mutations in patients that respond to anti-CTLA4 immunotherapy</article-title>
            <source>Nat. Genet.</source>
            <year>2016</year>
            <volume>48</volume>
            <fpage>1327</fpage>
            <lpage>1329</lpage>
            <pub-id pub-id-type="pmid">27668655</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3677</pub-id>
            <pub-id pub-id-type="pmcid">PMC5553281</pub-id>
          </element-citation>
        </ref>
        <ref id="CR30">
          <label>30.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shin</surname>
                <given-names>DS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Primary resistance to PD-1 blockade mediated by JAK1/2 mutations</article-title>
            <source>Cancer Discov.</source>
            <year>2017</year>
            <volume>7</volume>
            <fpage>188</fpage>
            <lpage>201</lpage>
            <pub-id pub-id-type="pmid">27903500</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-16-1223</pub-id>
            <pub-id pub-id-type="pmcid">PMC5296316</pub-id>
          </element-citation>
        </ref>
        <ref id="CR31">
          <label>31.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Sucker</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Acquired IFN-γ resistance impairs anti-tumor immunity and gives rise to T cell-resistant melanoma lesions</article-title>
            <source>Nat. Commun.</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>15440</fpage>
            <pub-id pub-id-type="pmid">28561041</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms15440</pub-id>
            <pub-id pub-id-type="pmcid">PMC5460020</pub-id>
          </element-citation>
        </ref>
        <ref id="CR32">
          <label>32.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Subramanian</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>
            <source>Proc. Natl Acad. Sci. USA</source>
            <year>2005</year>
            <volume>102</volume>
            <fpage>15545</fpage>
            <lpage>15550</lpage>
            <pub-id pub-id-type="pmid">16199517</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0506580102</pub-id>
            <pub-id pub-id-type="pmcid">PMC1239896</pub-id>
          </element-citation>
        </ref>
        <ref id="CR33">
          <label>33.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Liberzon</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The molecular signatures database hallmark gene-set collection</article-title>
            <source>Cell Syst.</source>
            <year>2015</year>
            <volume>1</volume>
            <fpage>417</fpage>
            <lpage>425</lpage>
            <pub-id pub-id-type="pmid">26771021</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cels.2015.12.004</pub-id>
            <pub-id pub-id-type="pmcid">PMC4707969</pub-id>
          </element-citation>
        </ref>
        <ref id="CR34">
          <label>34.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Auslander</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma</article-title>
            <source>Nat. Med.</source>
            <year>2018</year>
            <volume>24</volume>
            <fpage>1545</fpage>
            <lpage>1549</lpage>
            <pub-id pub-id-type="pmid">30127394</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-018-0157-9</pub-id>
            <pub-id pub-id-type="pmcid">PMC6693632</pub-id>
          </element-citation>
        </ref>
        <ref id="CR35">
          <label>35.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Fehrenbacher</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Atezolizumab versus docetaxel for patients with previously treated non-small cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <volume>387</volume>
            <fpage>1837</fpage>
            <lpage>1846</lpage>
            <pub-id pub-id-type="pmid">26970723</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(16)00587-0</pub-id>
          </element-citation>
        </ref>
        <ref id="CR36">
          <label>36.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Huang</surname>
                <given-names>AC</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma</article-title>
            <source>Nat. Med.</source>
            <year>2019</year>
            <volume>25</volume>
            <fpage>454</fpage>
            <lpage>461</lpage>
            <pub-id pub-id-type="pmid">30804515</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-019-0357-y</pub-id>
            <pub-id pub-id-type="pmcid">PMC6699626</pub-id>
          </element-citation>
        </ref>
        <ref id="CR37">
          <label>37.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Jiang</surname>
                <given-names>P</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response</article-title>
            <source>Nat. Med.</source>
            <year>2018</year>
            <volume>24</volume>
            <fpage>1550</fpage>
            <lpage>1558</lpage>
            <pub-id pub-id-type="pmid">30127393</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-018-0136-1</pub-id>
            <pub-id pub-id-type="pmcid">PMC6487502</pub-id>
          </element-citation>
        </ref>
        <ref id="CR38">
          <label>38.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Messina</surname>
                <given-names>JL</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?</article-title>
            <source>Sci. Rep.</source>
            <year>2012</year>
            <volume>2</volume>
            <fpage>765</fpage>
            <pub-id pub-id-type="pmid">23097687</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep00765</pub-id>
            <pub-id pub-id-type="pmcid">PMC3479449</pub-id>
          </element-citation>
        </ref>
        <ref id="CR39">
          <label>39.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ayers</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade</article-title>
            <source>J. Clin. Invest.</source>
            <year>2017</year>
            <volume>127</volume>
            <fpage>2930</fpage>
            <lpage>2940</lpage>
            <pub-id pub-id-type="pmid">28650338</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI91190</pub-id>
            <pub-id pub-id-type="pmcid">PMC5531419</pub-id>
          </element-citation>
        </ref>
        <ref id="CR40">
          <label>40.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ock</surname>
                <given-names>C-Y</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers</article-title>
            <source>Nat. Commun.</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>1050</fpage>
            <pub-id pub-id-type="pmid">29051489</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-017-01018-0</pub-id>
            <pub-id pub-id-type="pmcid">PMC5648801</pub-id>
          </element-citation>
        </ref>
        <ref id="CR41">
          <label>41.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Newman</surname>
                <given-names>AM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Robust enumeration of cell subsets from tissue expression profiles</article-title>
            <source>Nat. Methods</source>
            <year>2015</year>
            <volume>12</volume>
            <fpage>453</fpage>
            <lpage>457</lpage>
            <pub-id pub-id-type="pmid">25822800</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth.3337</pub-id>
            <pub-id pub-id-type="pmcid">PMC4739640</pub-id>
          </element-citation>
        </ref>
        <ref id="CR42">
          <label>42.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Jerby-Arnon</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade</article-title>
            <source>Cell</source>
            <year>2018</year>
            <volume>175</volume>
            <fpage>984</fpage>
            <lpage>997</lpage>
            <pub-id pub-id-type="pmid">30388455</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2018.09.006</pub-id>
            <pub-id pub-id-type="pmcid">PMC6410377</pub-id>
          </element-citation>
        </ref>
        <ref id="CR43">
          <label>43.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Barbie</surname>
                <given-names>DA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1</article-title>
            <source>Nature</source>
            <year>2009</year>
            <volume>462</volume>
            <fpage>108</fpage>
            <lpage>112</lpage>
            <pub-id pub-id-type="pmid">19847166</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature08460</pub-id>
            <pub-id pub-id-type="pmcid">PMC2783335</pub-id>
          </element-citation>
        </ref>
        <ref id="CR44">
          <label>44.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Riaz</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Tumor and microenvironment evolution during immunotherapy with nivolumab</article-title>
            <source>Cell</source>
            <year>2017</year>
            <volume>171</volume>
            <fpage>934</fpage>
            <lpage>949</lpage>
            <pub-id pub-id-type="pmid">29033130</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2017.09.028</pub-id>
            <pub-id pub-id-type="pmcid">PMC5685550</pub-id>
          </element-citation>
        </ref>
        <ref id="CR45">
          <label>45.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Weber</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab</article-title>
            <source>Ann. Oncol.</source>
            <year>2016</year>
            <volume>27</volume>
            <fpage>10470</fpage>
          </element-citation>
        </ref>
        <ref id="CR46">
          <label>46.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Amaria</surname>
                <given-names>RN</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma</article-title>
            <source>Nat. Med.</source>
            <year>2018</year>
            <volume>24</volume>
            <fpage>1649</fpage>
            <lpage>1654</lpage>
            <pub-id pub-id-type="pmid">30297909</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-018-0197-1</pub-id>
            <pub-id pub-id-type="pmcid">PMC6481682</pub-id>
          </element-citation>
        </ref>
        <ref id="CR47">
          <label>47.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Rodig</surname>
                <given-names>SJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma</article-title>
            <source>Sci. Transl. Med.</source>
            <year>2018</year>
            <volume>10</volume>
            <fpage>eaar3342</fpage>
            <pub-id pub-id-type="pmid">30021886</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aar3342</pub-id>
          </element-citation>
        </ref>
        <ref id="CR48">
          <label>48.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Johnson</surname>
                <given-names>DB</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy</article-title>
            <source>Nat. Commun.</source>
            <year>2016</year>
            <volume>7</volume>
            <fpage>10582</fpage>
            <pub-id pub-id-type="pmid">26822383</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms10582</pub-id>
            <pub-id pub-id-type="pmcid">PMC4740184</pub-id>
          </element-citation>
        </ref>
        <ref id="CR49">
          <label>49.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>McGranahan</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade</article-title>
            <source>Science</source>
            <year>2016</year>
            <volume>351</volume>
            <fpage>1463</fpage>
            <lpage>1469</lpage>
            <pub-id pub-id-type="pmid">26940869</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaf1490</pub-id>
            <pub-id pub-id-type="pmcid">PMC4984254</pub-id>
          </element-citation>
        </ref>
        <ref id="CR50">
          <label>50.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Morris</surname>
                <given-names>LGT</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival</article-title>
            <source>Oncotarget</source>
            <year>2016</year>
            <volume>7</volume>
            <fpage>10051</fpage>
            <lpage>10063</lpage>
            <pub-id pub-id-type="pmid">26840267</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.7067</pub-id>
            <pub-id pub-id-type="pmcid">PMC4891103</pub-id>
          </element-citation>
        </ref>
        <ref id="CR51">
          <label>51.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer</article-title>
            <source>Nat. Commun.</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>2193</fpage>
            <pub-id pub-id-type="pmid">29259186</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-017-02320-7</pub-id>
            <pub-id pub-id-type="pmcid">PMC5736752</pub-id>
          </element-citation>
        </ref>
        <ref id="CR52">
          <label>52.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Dewhurst</surname>
                <given-names>SM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution</article-title>
            <source>Cancer Discov.</source>
            <year>2014</year>
            <volume>4</volume>
            <fpage>175</fpage>
            <lpage>185</lpage>
            <pub-id pub-id-type="pmid">24436049</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-13-0285</pub-id>
            <pub-id pub-id-type="pmcid">PMC4293454</pub-id>
          </element-citation>
        </ref>
        <ref id="CR53">
          <label>53.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Weide</surname>
                <given-names>B</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab</article-title>
            <source>Clin. Cancer Res.</source>
            <year>2016</year>
            <volume>22</volume>
            <fpage>5487</fpage>
            <lpage>5496</lpage>
            <pub-id pub-id-type="pmid">27185375</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-16-0127</pub-id>
            <pub-id pub-id-type="pmcid">PMC5572569</pub-id>
          </element-citation>
        </ref>
        <ref id="CR54">
          <label>54.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Fransen</surname>
                <given-names>MF</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy</article-title>
            <source>JCI Insight</source>
            <year>2018</year>
            <volume>3</volume>
            <fpage>124507</fpage>
            <pub-id pub-id-type="pmid">30518694</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.124507</pub-id>
            <pub-id pub-id-type="pmcid">PMC6328025</pub-id>
          </element-citation>
        </ref>
        <ref id="CR55">
          <label>55.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Blank</surname>
                <given-names>CU</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</article-title>
            <source>Nat. Med.</source>
            <year>2018</year>
            <volume>24</volume>
            <fpage>1655</fpage>
            <lpage>1661</lpage>
            <pub-id pub-id-type="pmid">30297911</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-018-0198-0</pub-id>
          </element-citation>
        </ref>
        <ref id="CR56">
          <label>56.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cesano</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>nCounter PanCancer immune profiling panel (NanoString Technologies, Seattle, WA).</article-title>
            <source>J. Immunother. Cancer</source>
            <year>2015</year>
            <volume>3</volume>
            <fpage>42</fpage>
            <pub-id pub-id-type="pmid">26674611</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40425-015-0088-7</pub-id>
            <pub-id pub-id-type="pmcid">PMC4678588</pub-id>
          </element-citation>
        </ref>
        <ref id="CR57">
          <label>57.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Fisher</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries</article-title>
            <source>Genome Biol.</source>
            <year>2011</year>
            <volume>12</volume>
            <fpage>R1</fpage>
            <pub-id pub-id-type="pmid">21205303</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/gb-2011-12-1-r1</pub-id>
            <pub-id pub-id-type="pmcid">PMC3091298</pub-id>
          </element-citation>
        </ref>
        <ref id="CR58">
          <label>58.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gnirke</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing</article-title>
            <source>Nat. Biotechnol.</source>
            <year>2009</year>
            <volume>27</volume>
            <fpage>182</fpage>
            <lpage>189</lpage>
            <pub-id pub-id-type="pmid">19182786</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.1523</pub-id>
            <pub-id pub-id-type="pmcid">PMC2663421</pub-id>
          </element-citation>
        </ref>
        <ref id="CR59">
          <label>59.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cibulskis</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>ContEst: estimating cross-contamination of human samples in next generation sequencing data</article-title>
            <source>Bioinformatics</source>
            <year>2011</year>
            <volume>27</volume>
            <fpage>2601</fpage>
            <lpage>2602</lpage>
            <pub-id pub-id-type="pmid">21803805</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btr446</pub-id>
            <pub-id pub-id-type="pmcid">PMC3167057</pub-id>
          </element-citation>
        </ref>
        <ref id="CR60">
          <label>60.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cibulskis</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples</article-title>
            <source>Nat. Biotechnol.</source>
            <year>2013</year>
            <volume>31</volume>
            <fpage>213</fpage>
            <lpage>219</lpage>
            <pub-id pub-id-type="pmid">23396013</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.2514</pub-id>
            <pub-id pub-id-type="pmcid">PMC3833702</pub-id>
          </element-citation>
        </ref>
        <ref id="CR61">
          <label>61.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Costello</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation</article-title>
            <source>Nucleic Acids Res.</source>
            <year>2013</year>
            <volume>41</volume>
            <fpage>e67</fpage>
            <pub-id pub-id-type="pmid">23303777</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gks1443</pub-id>
            <pub-id pub-id-type="pmcid">PMC3616734</pub-id>
          </element-citation>
        </ref>
        <ref id="CR62">
          <label>62.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Saunders</surname>
                <given-names>CT</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs</article-title>
            <source>Bioinformatics</source>
            <year>2012</year>
            <volume>28</volume>
            <fpage>1811</fpage>
            <lpage>1817</lpage>
            <pub-id pub-id-type="pmid">22581179</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bts271</pub-id>
          </element-citation>
        </ref>
        <ref id="CR63">
          <label>63.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ramos</surname>
                <given-names>AH</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Oncotator: cancer variant annotation tool</article-title>
            <source>Hum. Mutat.</source>
            <year>2015</year>
            <volume>36</volume>
            <fpage>E2423</fpage>
            <lpage>E2429</lpage>
            <pub-id pub-id-type="pmid">25703262</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/humu.22771</pub-id>
            <pub-id pub-id-type="pmcid">PMC7350419</pub-id>
          </element-citation>
        </ref>
        <ref id="CR64">
          <label>64.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shukla</surname>
                <given-names>SA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes</article-title>
            <source>Nat. Biotechnol.</source>
            <year>2015</year>
            <volume>33</volume>
            <fpage>1152</fpage>
            <pub-id pub-id-type="pmid">26372948</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.3344</pub-id>
            <pub-id pub-id-type="pmcid">PMC4747795</pub-id>
          </element-citation>
        </ref>
        <ref id="CR65">
          <label>65.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Nielsen</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and HLA-B locus protein of known sequence</article-title>
            <source>PloS ONE</source>
            <year>2007</year>
            <volume>2</volume>
            <fpage>e796</fpage>
            <pub-id pub-id-type="pmid">17726526</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0000796</pub-id>
            <pub-id pub-id-type="pmcid">PMC1949492</pub-id>
          </element-citation>
        </ref>
        <ref id="CR66">
          <label>66.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Olshen</surname>
                <given-names>AB</given-names>
              </name>
              <name name-style="western">
                <surname>Venkatraman</surname>
                <given-names>ES</given-names>
              </name>
              <name name-style="western">
                <surname>Lucito</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Wigler</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Circular binary segmentation for the analysis of array-based DNA copy number data</article-title>
            <source>Biostatistics</source>
            <year>2004</year>
            <volume>5</volume>
            <fpage>557</fpage>
            <lpage>572</lpage>
            <pub-id pub-id-type="pmid">15475419</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/biostatistics/kxh008</pub-id>
          </element-citation>
        </ref>
        <ref id="CR67">
          <label>67.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Carter</surname>
                <given-names>SL</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Absolute quantification of somatic DNA alterations in human cancer</article-title>
            <source>Nat. Biotechnol.</source>
            <year>2012</year>
            <volume>30</volume>
            <fpage>413</fpage>
            <lpage>421</lpage>
            <pub-id pub-id-type="pmid">22544022</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.2203</pub-id>
            <pub-id pub-id-type="pmcid">PMC4383288</pub-id>
          </element-citation>
        </ref>
        <ref id="CR68">
          <label>68.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Brastianos</surname>
                <given-names>PK</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets</article-title>
            <source>Cancer Discov</source>
            <year>2015</year>
            <volume>5</volume>
            <fpage>1164</fpage>
            <lpage>1177</lpage>
            <pub-id pub-id-type="pmid">26410082</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-15-0369</pub-id>
            <pub-id pub-id-type="pmcid">PMC4916970</pub-id>
          </element-citation>
        </ref>
        <ref id="CR69">
          <label>69.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lee</surname>
                <given-names>DD</given-names>
              </name>
              <name name-style="western">
                <surname>Seung</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Learning the parts of objects by non-negative matrix factorization</article-title>
            <source>Nature</source>
            <year>1999</year>
            <volume>401</volume>
            <fpage>788</fpage>
            <lpage>791</lpage>
            <pub-id pub-id-type="pmid">10548103</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/44565</pub-id>
          </element-citation>
        </ref>
        <ref id="CR70">
          <label>70.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Brunet</surname>
                <given-names>JP</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Metagenes and molecular pattern discovery using matrix factorization</article-title>
            <source>Proc. Natl Acad. Sci. USA</source>
            <year>2004</year>
            <volume>101</volume>
            <fpage>4164</fpage>
            <lpage>4169</lpage>
            <pub-id pub-id-type="pmid">15016911</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0308531101</pub-id>
            <pub-id pub-id-type="pmcid">PMC384712</pub-id>
          </element-citation>
        </ref>
        <ref id="CR71">
          <label>71.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gehring</surname>
                <given-names>JS</given-names>
              </name>
              <name name-style="western">
                <surname>Fischer</surname>
                <given-names>B</given-names>
              </name>
              <name name-style="western">
                <surname>Lawrence</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Huber</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>SomaticSignatures: inferring mutational signatures from single-nucleotide variants</article-title>
            <source>Bioinformatics</source>
            <year>2015</year>
            <volume>31</volume>
            <fpage>3673</fpage>
            <lpage>3675</lpage>
            <pub-id pub-id-type="pmid">26163694</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btv408</pub-id>
            <pub-id pub-id-type="pmcid">PMC4817139</pub-id>
          </element-citation>
        </ref>
        <ref id="CR72">
          <label>72.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gaujoux</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Seoighe</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A flexible R package for nonnegative matrix factorization</article-title>
            <source>BMC Bioinformatics</source>
            <year>2010</year>
            <volume>11</volume>
            <fpage>367</fpage>
            <pub-id pub-id-type="pmid">20598126</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2105-11-367</pub-id>
            <pub-id pub-id-type="pmcid">PMC2912887</pub-id>
          </element-citation>
        </ref>
        <ref id="CR73">
          <label>73.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Forbes</surname>
                <given-names>SA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>COSMIC: exploring the world’s knowledge of somatic mutations in human cancer</article-title>
            <source>Nucleic Acids Res.</source>
            <year>2015</year>
            <volume>43</volume>
            <fpage>D805</fpage>
            <lpage>D811</lpage>
            <pub-id pub-id-type="pmid">25355519</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gku1075</pub-id>
            <pub-id pub-id-type="pmcid">PMC4383913</pub-id>
          </element-citation>
        </ref>
        <ref id="CR74">
          <label>74.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Dobin</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>STAR: ultrafast universal RNA-seq aligner</article-title>
            <source>Bioinformatics</source>
            <year>2013</year>
            <volume>29</volume>
            <fpage>15</fpage>
            <lpage>21</lpage>
            <pub-id pub-id-type="pmid">23104886</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bts635</pub-id>
            <pub-id pub-id-type="pmcid">PMC3530905</pub-id>
          </element-citation>
        </ref>
        <ref id="CR75">
          <label>75.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name name-style="western">
                <surname>Dewey</surname>
                <given-names>CN</given-names>
              </name>
            </person-group>
            <article-title>RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome</article-title>
            <source>BMC Bioinformatics</source>
            <year>2011</year>
            <volume>12</volume>
            <fpage>323</fpage>
            <pub-id pub-id-type="pmid">21816040</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2105-12-323</pub-id>
            <pub-id pub-id-type="pmcid">PMC3163565</pub-id>
          </element-citation>
        </ref>
        <ref id="CR76">
          <label>76.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Durinck</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis</article-title>
            <source>Bioinformatics</source>
            <year>2005</year>
            <volume>21</volume>
            <fpage>3439</fpage>
            <lpage>3440</lpage>
            <pub-id pub-id-type="pmid">16082012</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bti525</pub-id>
          </element-citation>
        </ref>
        <ref id="CR77">
          <label>77.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Thorsson</surname>
                <given-names>V</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The immune landscape of cancer</article-title>
            <source>Immunity</source>
            <year>2018</year>
            <volume>48</volume>
            <fpage>812</fpage>
            <lpage>830</lpage>
            <pub-id pub-id-type="pmid">29628290</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2018.03.023</pub-id>
            <pub-id pub-id-type="pmcid">PMC5982584</pub-id>
          </element-citation>
        </ref>
        <ref id="CR78">
          <label>78.</label>
          <mixed-citation publication-type="other">Davidson-Pilon C. et al. CamDavidsonPilon/lifelines v.0.18.5. <italic toggle="yes">Zenodo</italic>10.5281/zenodo.2562267 (2019).</mixed-citation>
        </ref>
        <ref id="CR79">
          <label>79.</label>
          <mixed-citation publication-type="other">Waksom M. et al. mwaskom/seaborn v.0.8.1 <italic toggle="yes">Zenodo</italic>10.5281/zenodo.883859 (2017).</mixed-citation>
        </ref>
      </ref-list>
    </back>
  </article>
</pmc-articleset>
